A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk.
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis.
A species of GAMMARETROVIRUS causing leukemia, lymphosarcoma, immune deficiency, or other degenerative diseases in cats. Several cellular oncogenes confer on FeLV the ability to induce sarcomas (see also SARCOMA VIRUSES, FELINE).
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from spontaneous leukemia in AKR strain mice.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Disease having a short and relatively severe course.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.
The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.
Mapping of the KARYOTYPE of a cell.
An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.
A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.
A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).
Established cell cultures that have the potential to propagate indefinitely.
A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
A general term for various neoplastic diseases of the lymphoid tissue.
A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Immunological rejection of leukemia cells following bone marrow transplantation.
A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A receptor subunit that combines with CYTOKINE RECEPTOR GP130 to form the dual specificity receptor for LEUKEMIA INHIBITORY FACTOR and ONCOSTATIN M. The subunit is also a component of the CILIARY NEUROTROPHIC FACTOR RECEPTOR. Both membrane-bound and secreted isoforms of the receptor subunit exist due to ALTERNATIVE SPLICING of its mRNA. The secreted isoform is believed to act as an inhibitory receptor, while the membrane-bound form is a signaling receptor.
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A spectrum of disorders characterized by clonal expansions of the peripheral blood LYMPHOCYTE populations known as large granular lymphocytes which contain abundant cytoplasm and azurophilic granules. Subtypes develop from either CD3-negative NATURAL KILLER CELLS or CD3-positive T-CELLS. The clinical course of both subtypes can vary from spontaneous regression to progressive, malignant disease.
Examination of CHROMOSOMES to diagnose, classify, screen for, or manage genetic diseases and abnormalities. Following preparation of the sample, KARYOTYPING is performed and/or the specific chromosomes are analyzed.
Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
The return of a sign, symptom, or disease after a remission.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
Virus diseases caused by the RETROVIRIDAE.
Progenitor cells from which all blood cells derive.
A cell line derived from cultured tumor cells.
Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.
Transcriptional trans-acting proteins of the promoter elements found in the long terminal repeats (LTR) of HUMAN T-LYMPHOTROPIC VIRUS 1 and HUMAN T-LYMPHOTROPIC VIRUS 2. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the LTR.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Inorganic or organic compounds that contain arsenic.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
A species of GAMMARETROVIRUS causing leukemia in the gibbon ape. Natural transmission is by contact.
DNA present in neoplastic tissue.
A specific pair of GROUP G CHROMOSOMES of the human chromosome classification.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.
Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A neoplastic disease of cats frequently associated with feline leukemia virus infection.
A subdiscipline of genetics which deals with the cytological and molecular analysis of the CHROMOSOMES, and location of the GENES on chromosomes, and the movements of chromosomes during the CELL CYCLE.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS).
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A lymphoid neoplastic disease in cattle caused by the bovine leukemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukemia but the presence of malignant cells in the blood is not a consistent finding.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antibodies produced by a single clone of cells.
RNA present in neoplastic tissue.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Elements of limited time intervals, contributing to particular results or situations.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
The short, acrocentric human chromosomes, called group G in the human chromosome classification. This group consists of chromosome pairs 21 and 22 and the Y chromosome.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of >20% MAST CELLS, multi-organ failure and a short survival.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Cell surface receptors formed from the dimerization of LIF RECEPTOR ALPHA SUBUNIT with CYTOKINE RECEPTOR GP130. Although originally described as receptors for LEUKEMIA INHIBITORY FACTOR these receptors also bind the closely-related protein ONCOSTATIN M and are referred to as both LIF receptors and type I oncostatin M receptors.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from radiation-induced lymphomas in C57BL mice. It is leukemogenic, thymotrophic, can be transmitted vertically, and replicates only in vivo.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Agents that inhibit PROTEIN KINASES.
Duplex DNA sequences in eukaryotic chromosomes, corresponding to the genome of a virus, that are transmitted from one cell generation to the next without causing lysis of the host. Proviruses are often associated with neoplastic cell transformation and are key features of retrovirus biology.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Antimetabolites that are useful in cancer chemotherapy.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
A genus in the family RETROVIRIDAE consisting of exogenous horizontally-transmitted viruses found in a few groups of mammals. Infections caused by these viruses include human B- or adult T-cell leukemia/lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), and bovine leukemia (ENZOOTIC BOVINE LEUKOSIS). The type species is LEUKEMIA VIRUS, BOVINE.
A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.
Deoxyribonucleic acid that makes up the genetic material of viruses.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A method (first developed by E.M. Southern) for detection of DNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED).
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
The action of a drug in promoting or enhancing the effectiveness of another drug.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)
Nucleosides containing arabinose as their sugar moiety.
An anthracenedione-derived antineoplastic agent.
A genus of RETROVIRIDAE comprising endogenous sequences in mammals, related RETICULOENDOTHELIOSIS VIRUSES, AVIAN, and a reptilian virus. Many species contain oncogenes and cause leukemias and sarcomas.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The functional hereditary units of VIRUSES.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Proto-oncogene protein bcr is a serine-threonine kinase that functions as a negative regulator of CELL PROLIFERATION and NEOPLASTIC CELL TRANSFORMATION. It is commonly fused with cellular abl protein to form BCR-ABL FUSION PROTEINS in PHILADELPHIA CHROMOSOME positive LEUKEMIA patients.
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Tetracyclic spiro-BENZAZEPINES isolated from the seeds of CEPHALOTAXUS. They are esters of the alkaloid cephalotaxine and may be effective as antineoplastic agents.
An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

Purine nucleoside phosphorylase in chronic lymphocytic leukemia (CLL). (1/1986)

Purine nucleoside phosphorylase (PNP), the enzyme schematically next to adenosine deaminase in the purine salvage pathway, has been demonstrated cytochemically in peripheral blood lymphocytes of healthy subjects and chronic lymphocytic leukemia (CLL) patients. The enzyme activity is confined to the cytosol. In healthy subjects the majority of lymphocytes are strongly reactive for PNP, whereas the rest are devoid of cytochemically demonstrable activity. The percentage of PNP-positive cells largely corresponds to the number of E rosette-forming cells and is inversely proportional to the number of Ig-bearing cells. In six of seven CLL patients studied only a minor percentage of the lymphocytes showed strong PNP activity, whereas the large majority (88%--98%) possessed trace activity. Such patients have a high number of Ig-bearing cells and a low number of E rosette-forming cells. A different pattern of markers was found in the lymphocytes of the seventh CLL patient: 66% were strongly reactive for PNP, an important number formed E rosettes, and a minor percentage were Ig bearing. These data indicate that PNP can be useful as a "nonmembrane" marker in the differentiation of the B and T cell origin in CLL and deserves to be studied in other lymphoproliferative disorders.  (+info)

Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. (2/1986)

Tumor cell resistance to certain chemotherapeutic agents may result in cross-resistance to related antineoplastic agents. To study cross-resistance among inhibitors of ribonucleotide reductase, we developed hydroxyurea-resistant (HU-R) CCRF-CEM cells. These cells were 6-fold more resistant to hydroxyurea than the parent hydroxyurea-sensitive (HU-S) cell line and displayed an increase in the mRNA and protein of the R2 subunit of ribonucleotide reductase. We examined whether HU-R cells were cross-resistant to gemcitabine, a drug that blocks cell proliferation by inhibiting ribonucleotide reductase and incorporating itself into DNA. Contrary to our expectation, HU-R cells had an increased sensitivity to gemcitabine. The IC50 of gemcitabine was 0.061 +/- 0.03 microM for HU-R cells versus 0.16 +/- 0.02 microM for HU-S cells (P = 0.005). The cellular uptake of [3H]gemcitabine and its incorporation into DNA were increased in HU-R cells. Over an 18-h incubation with radiolabeled gemcitabine (0.25 microM), gemcitabine uptake was 286 +/- 37.3 fmol/10(6) cells for HU-R cells and 128 +/- 8.8 fmol/10(6) cells for HU-S cells (P = 0.03). The incorporation of gemcitabine into DNA was 75 +/- 6.7 fmol/10(6) cells for HU-R cells versus 22 +/- 0.6 fmol/10(6) cells for HU-S cells (P < 0.02). Our studies suggest that the increased sensitivity of HU-R cells to gemcitabine results from increased drug uptake by these cells. This, in turn, favors the incorporation of gemcitabine into DNA, resulting in enhanced cytotoxicity. The increased sensitivity of malignant cells to gemcitabine after the development of hydroxyurea resistance may be relevant to the design of chemotherapeutic trials with these drugs.  (+info)

Skin reaction and antibody responses in guinea-pigs sensitized to human leukaemia cells or their nuclei in combination with Bacillus Calmette-Guerin. (3/1986)

Guinea-pigs sensitized by subcutaneous injection of chronic lymphatic leukaemia (CLL) cells combined with Bacillus Calmette-Guerin (BCG) displayed good skin reacitons 24 and 48 h after challenge with CLL cells. Equally good responses were also demonstrated using nuclei from the leukaemic cells in combination with BCG. These reactions were significantly greater than those produced in the same manner but without BCG. Sera form the animals were examined for the presence of antibodies against CLL cells by cytotoxicity and immunofluorescence techniques. Only samples from guinea-pigs innoculated with CLL cells were found to contain significant antibodies. Histological examination showed that whereas leukaemic cells persisted at the sensitizing injection site leukaemic cell nuclei could not be visualized. It is suggested that because leukaemic cell nuclei in combination with BCG are able to induce good skin reactivity without provoking a vigorous humoral antibody response they may have possible advantages over leukaemic cells when used for immunotherapy.  (+info)

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. (4/1986)

The product of the Philadelphia chromosome (Ph) translocation, the BCR/ABL oncogene, exists in three principal forms (P190, P210, and P230 BCR/ABL) that are found in distinct forms of Ph-positive leukemia, suggesting the three proteins have different leukemogenic activity. We have directly compared the tyrosine kinase activity, in vitro transformation properties, and in vivo leukemogenic activity of the P190, P210, and P230 forms of BCR/ABL. P230 exhibited lower intrinsic tyrosine kinase activity than P210 and P190. Although all three oncogenes transformed both myeloid (32D cl3) and lymphoid (Ba/F3) interleukin (IL)-3-dependent cell lines to become independent of IL-3 for survival and growth, their ability to stimulate proliferation of Ba/F3 lymphoid cells differed and correlated directly with tyrosine kinase activity. In a murine bone marrow transduction/transplantation model, the three forms of BCR/ABL were equally potent in the induction of a chronic myeloid leukemia (CML)-like myeloproliferative syndrome in recipient mice when 5-fluorouracil (5-FU)-treated donors were used. Analysis of proviral integration showed the CML-like disease to be polyclonal and to involve multiple myeloid and B lymphoid lineages, implicating a primitive multipotential target cell. Secondary transplantation revealed that only certain minor clones gave rise to day 12 spleen colonies and induced disease in secondary recipients, suggesting heterogeneity among the target cell population. In contrast, when marrow from non- 5-FU-treated donors was used, a mixture of CML-like disease, B lymphoid acute leukemia, and macrophage tumors was observed in recipients. P190 BCR/ABL induced lymphoid leukemia with shorter latency than P210 or P230. The lymphoid leukemias and macrophage tumors had provirus integration patterns that were oligo- or monoclonal and limited to the tumor cells, suggesting a lineage-restricted target cell with a requirement for additional events in addition to BCR/ABL transduction for full malignant transformation. These results do not support the hypothesis that P230 BCR/ABL induces a distinct and less aggressive form of CML in humans, and suggest that the rarity of P190 BCR/ABL in human CML may reflect infrequent BCR intron 1 breakpoints during the genesis of the Ph chromosome in stem cells, rather than intrinsic differences in myeloid leukemogenicity between P190 and P210.  (+info)

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. (5/1986)

Microtubules are linear polymers of alpha- and beta-tubulin heterodimers and are the major constituents of mitotic spindles, which are essential for the separation of chromosomes during mitosis. Here we describe a synthetic compound, 2-fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene (T138067), which covalently and selectively modifies the beta1, beta2, and beta4 isotypes of beta-tubulin at a conserved cysteine residue, thereby disrupting microtubule polymerization. Cells exposed to T138067 become altered in shape, indicating a collapse of the cytoskeleton, and show an increase in chromosomal ploidy. Subsequently, these cells undergo apoptosis. Furthermore, T138067 exhibits cytotoxicity against tumor cell lines that exhibit substantial resistance to vinblastine, paclitaxel, doxorubicin, and actinomycin D. T138067 is also equally efficacious in inhibiting the growth of sensitive and multidrug-resistant human tumor xenografts in athymic nude mice. These observations suggest that T138067 may be clinically useful for the treatment of multidrug-resistant tumors.  (+info)

Detection of p53 gene mutations in human leukemia by PCR-SSCP analysis and direct nucleotide sequencing. (6/1986)

OBJECTIVE: To look for mutations of the p53 gene in leukemic patients and study the relationship between abnormalities in p53 gene and leukemogenesis. METHODS: The peripheral blood and Bone Marrow Samples were collected from 36 patients with various leukemia types including 14 cases of lymphocytic leukemia [8 cases of acute lymphocytic leukemia (ALL), 4 cases of chronic lymphocytic leukemia (CLL), 2 cases of hairy cell leukemia (HCL)] and 22 cases of myelocytic leukemia [11 cases of acute nonlymphocytic leukemia (ANLL), 11 cases of chronic myelocytic leukemia (CML)]. DNA structures of exon 5-8 of the p53 gene were scanned by PCR-SSCP (single strand conformation polymorphism analysis of polymerase chain reaction products). The appropriate DNA fragments were amplified, Purified and sequenced directly. RESULTS: By PCR-SSCP analysis, shifts in electrophoretic mobility of the p53 gene were detected in 3 of 14 patients with lymphocytic leukemia (2 ALL and 1 CLL), but none in 22 patients with myelocytic leukemia including one in blastic crisis. Direct nucleotide sequencing in one patient with ALL showed transition of CTG to CAG at codon 257 of exon 7, resulting in a change of its encoded amino acids from aspartic acid to valine. To our knowledge, the mutation at this codon has not been previously reported hitherto. CONCLUSIONS: The p53 gene mutations are specifically associated with lymphocytic leukemia. Alternations of the p53 gene may play a certain role in leukemogenesis in some cases of lymphocytic leukemia.  (+info)

Effects of spin labeled derivatives of podophyllotoxin on cell cycle and macromolecular synthesis in human lymphoid leukemia Molt 4B cells. (7/1986)

AIM: To examine the effect of the spin labeled derivatives of podophyllotoxin, N-podophyllic acid-N"-[4-(2,2,6,6-tetramethyl-1-piperidinyloxy)] thiosemicarbazide (GP4) and 4-[4"-(2",2",6",6"-tetramethyl-1"-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin (GP7) on the cell cycle and macromolecular synthesis of human lymphoid leukemia Molt 4B cells in vitro. METHODS: MTT assay, 3H incorporation, and flow cytometer were used. RESULTS: GP4, GP7, and etoposide 0.02-100 mmol.L-1 cultured for 48 h inhibited the proliferation of human lymphoid leukemia Molt 4B cells. IC50 values of GP4, GP7, and etoposide were 0.11, 4.7, and 1.6 mmol.L-1, respectively. DNA and protein syntheses were obviously suppressed by GP4, GP7, and etoposide 10 mmol.L-1 for 48 h. After Molt 4B cells were treated with GP4, GP7, and etoposide 10 mmol.L-1 for 6 and 12 h, the mitotic index was increased by GP4 and reduced by GP7 and etoposide. According to flow cytometric BrdU/DNA analysis, GP4 slightly retarded S phase and mainly arrested cell cycle progression in G2/M phase, whereas GP7 similar to etoposide induced cells accumulated at S phase and retarded the cells in G2 phase. CONCLUSION: GP4 and GP7 inhibit the proliferation of Molt 4B cells, but the mechanisms are different.  (+info)

Cleavage of the ALL1 gene in acute lymphoid leukemia before treatment disappears in relapse. (8/1986)

BACKGROUND AND OBJECTIVE: ALL1 gene rearrangements are frequently found in secondary acute leukemias (ALs). A site-specific cleavage of the ALL1 gene in a consensus sequence for topoisomerase II recognition has been considered to be the initial step leading to ALL1 rearrangement and subsequent therapy-related AL. The aim of the present study was to evaluate this cleavage in our patients, to analyze whether it is a laboratory-produced artefact and to check whether it persists or causes a real ALL1 gene rearrangement at relapse. DESIGN AND METHODS: We studied ALL1 rearrangement in 74 cases of AL before treatment by Southern blot avoiding room temperature exposure or delay in processing the samples which could produce ALL1 cleavage. DNA was available for two cases with ALL1 cleavage; it was analyzed by three different Southern blots in one and two in the other. One case with ALL1 cleavage was also studied in relapse. RESULTS: The presence of the cleavage of the ALL1 DNA was found in 3 of 74 (4%) patients. Two of these three patients had the ALL1 cleavage in three and two different analyses. One case was positive for ALL1 cleavage at diagnosis, but negative for both ALL1 cleavage and ALL1 rearrangement at relapse. INTERPRETATION AND CONCLUSIONS: The fact that a constant pattern was obtained from the same patients in different DNA preparations, supports the notion that ALL1 cleavage is not a laboratory artefact. The absence of the cleavage in a sample from a relapsed patient suggests that the subclone with the ALL1 cleavage, in this case, did not play a clear role in the pathogenesis of disease recurrence.  (+info)

Treatment for Chronic Lymphatic Leukaemia to Replace Chemotherapy. Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and lymphoid tissues.
A case report of a patient who developed fatal pneumocystis pneumonia while in remission from acute lymphatic leukaemia is presented.
The close relationship which seems to exist between lymphocytes and plasma cells has recently been the subject of much discussion.1, 2 The frequent occurrence of apparently identical serum protein abnormalities in patients with malignant lymphoma, lymphatic leukemia and multiple myeloma, as demonstrated by paper electrophoresis, has been felt to be of particular significance. The consensus seems to be that plasma cells probably represent transitional forms of lymphocytes, as had been suggested by the work of Sundberg3 and others,4 and that both are capable of synthesizing abnormal serum proteins.. Although serum proteins of the myeloma type have occasionally been reported in ...
Die Universität zu Köln ist eine Exzellenzuniversität mit dem klassischen Fächerspektrum einer Volluniversität. Als eine der größen Hochschulen Europas arbeitet sie in Forschung und Lehre auch international auf höchstem Niveau.
A cobalamin-dependent N5-methyltetra-hydrofolate-homocysteine methyltransferase (methyl-transferase) was demonstrated in unfractioned extracts of human normal and leukemia leukocytes. Activity was substantially reduced in the absence of an added cobalamin derivative. Presumably, this residual activity reflects the endogeneous level of holoenzyme. Enzyme activity was notably higher in lymphoid cells than in myeloid cells. Thus, mean specific activities (+/-SD) were: chronic lymphocytic leukemia lymphocytes, 2.15+/-1.16; normal lymphocytes, 0.91+/-0.59; normal mature granulocytes, 0.15+/-0.10; chronic myelocytic leukemia granulocytes, barely detectable activity. Properties of leukocytes enzymes resembled those of methyltransferases previously studied in bacteria and other animal cells. Granulocytes and chronic myelocytic leukemia cells contain a factor or factors that inhibits Escherichia coli enzyme. The data suggest that the prominence of this cobalamin-dependent enzyme in lymphocytes and other ...
Any information provided here is, despite best effort to keep it as accurate and precise as possible, of a general nature and cannot substitute for the advice of a licensed professional ...
This study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed B-cell chronic lymphatic leukemia.
The hepatitis C virus (HCV) was characterised in 1989. HCV was transmitted through transfusion of blood/blood products, but injection drug use is now the most common route of transmission. The infection is usually asymptomatic but becomes chronic in about 75%, and in 20 years 15-25% develops liver cirrhosis, with a risk for liver failure and liver cancer. HCV has also been associated with lymphoproliferative disorders. The aim of this thesis was to study morbidity and mortality in a national, population-based cohort of HCV-infected individuals. The study population consisted of all persons with a diagnosed HCV-infection recorded in the national surveillance database. This file was linked to other national registers to obtain information of emigration, deaths, cancers, and inpatient care. All personal identifiers were removed before analysis.. In Paper I the standardized incidence ratios (SIR) for Hodgkins and non-Hodgkins lymphoma (NHL), multiple myeloma, acute and chronic lymphatic leukaemia, ...
Natural killer (NK) cell therapy is used in pediatrics for children with relapsed lymphoid leukemia. These patients normally have a resistance to chemotherapy, therefore, in order to continue on, must receive some kind of therapy. In some cases, NK cell therapy is a choice.[8] NK cells are known for their ability to eradicate tumor cells without any prior sensitization to them.[9] One problem when using NK cells in order to fight off lymphoid leukemia is the fact that it is hard to amount enough of them to be effective.[9] One can receive donations of NK cells from parents or relatives through bone marrow transplants. There are also the issues of cost, purity and safety.[10] Unfortunately, there is always the possibility of Graft vs host disease while transplanting bone marrow. NK cell therapy is a possible treatment for many different cancers such as Malignant glioma.[11] ...
Bone Marrow is obtained from adult Acute Lymphoid Leukemia patients. Bone Marrow-Mononuclear Cells are isolated from bone marrow by diluting the whole bone marrow with phosphate buffered saline and using gradient separation techniques. Mononuclear Cells can be processed to isolate subpopulations. Acute Lymphoid Leukemia-Bone Marrow-Mononuclear Cells are available in the newly diagnosed and relapsed/refractory stages ...
About 3,800 new cases of acute lymphocytic leukemia (ALL) are diagnosed each year in the United States. It is the most common type of leukemia under the age of 15. Children are most likely to develop the disease, but it can occur at any age. Acute lymphocytic leukemia may be called by several names, including acute lymphoid leukemia and acute lymphoblastic leukemia.. ALL results from an acquired (not inherited) genetic injury to the DNA of a single cell in the bone marrow. The disease is often referred to as acute lymphoblastic leukemia because the leukemic cell that replaces the normal marrow is the (leukemic) lymphoblast. The effects are: 1) the uncontrolled and exaggerated growth and accumulation of cells called lymphoblasts or leukemic blasts, which fail to function as normal blood cells and 2) the blockade of the production of normal marrow cells, leading to a deficiency of red cells (anemia), platelets (thrombocytopenia), and normal white cells (especially neutrophils, i.e., ...
Acute lymphoblastic leukaemia. In acute lymphoblastic leukaemia (ALL) the bone marrow makes large numbers of abnormal immature lymphocytes called lymphoblasts. There are various sub-types of ALL. For example, the abnormal lymphoblasts can be immature B or T lymphocytes. ALL can occur at any age, but about 6 in 10 cases occur in children. It is the most common form of leukaemia to affect children.. Acute myeloid leukaemia. In acute myeloid leukaemia (AML) the bone marrow makes large numbers of abnormal immature white blood cells which are derived from a myeloid stem cell. The abnormal immature cells are called blasts. There are various sub-types of AML, depending on exactly what cell type becomes cancerous and at what stage in the maturing process. AML is an uncommon disease. Most cases occur in people aged over 50.. Chronic lymphocytic leukaemia. In chronic lymphocytic leukaemia (CLL) you have many abnormal B lymphocytes. Typically, CLL develops and progresses very slowly - over months or years, ...
Thierfelder, S; Rodt, H; and Netzel, B, Suppression of lymphatic leukemia transferred [email protected]@@ring synge bone marrow transplantation. Abstr. (1977). Subject Strain Bibliography 1977. 447 ...
Acute lymphatic leukemia (ALL) is the most common cancer in children under the age of 14 years. With optimum treatment, approximately 75 % of children are currently cured, but the treatment consists of severe chemotherapy with many side effects. In collaboration with international research teams, scientists at VIB, KU Leuven and UZ Leuven have identified new genetic mutations that lead to T-ALL, a variant of ALL. They have unmasked the ribosome - the molecular machine in the cell that is involved in the production of proteins - as a weak spot in leukemia cells. Their research has also shown that there is a difference in T-ALL between adults and children. Both findings can be important in the search for improved treatments for T-ALL. ...
743 TRAIL (TNF-related apoptosis inducing ligand) and agonistic anti TRAIL-receptor antibodies exert two main functions on tumor cells: Induction of apoptosis in group A tumor cells and induction of proliferation in group P tumor cells. While induction of apoptosis is the aimed effect during putative anti-tumor therapy using TRAIL, TRAIL-induced tumor cell proliferation should be prevented. Here we report that group P tumor cells characterized by TRAIL-mediated proliferation were found among primary cells of different origin, e.g. of adult patients with acute myeloid leukemia and of children with neuroblastoma or acute lymphatic leukemia. TRAIL-induced proliferation was found in primary tumor cells in the presence of cytotoxic drugs. In primary cells, TRAIL-induced proliferation was associated with resistance towards apoptosis induction by the CD95 system and / or TNF. Inhibition of NFκB disabled TRAIL-induced tumor cell proliferation. In cell lines, loss of caspase-8 or transfection of ...
Glucocorticoids (GC) induce programmed cell death (apoptosis) in immature lymphocytes and are an essential component in the therapy of acute lymphatic leukemia. The mechanism underlying GC-induced apoptosis particularly in leukemia cells is, however, not well understood. Most forms of apoptosis seem …
The duration of the study for the patients will include a period for screening of up to 14 days. The cycle duration is 42 days. Patients will continue study treatment as long as clinical benefit is possible or until disease progression, unacceptable adverse reaction, patients decision to stop treatment, or other reason of discontinuation. After study treatment discontinuation patients will return to the study site 30 days after the last administration of SAR440234 for end of treatment assessments. Patients without documented disease progression at the end of a treatment visit who have not yet started treatment with another anti-cancer therapy will proceed with monthly follow-up visits until initiation of another anti-cancer therapy, disease progression, or study cut-off date, whichever comes first ...
StemExpress offers an assortment of peripheral blood products, including cells, leukopaks, macrophages, whole peripheral blood, blood plasma and more.
MODEL RELEASED. Anaemia. Pale face of a 4 year old boy who is anaemic due to acute lymphocytic leukaemia. This is a cancer of the white blood cells (leucocytes), specifically the lymphocytes, which are responsible for fighting infection. The disease leads to their abnormal proliferation in the bone marrow and organs of the lymph system, which can result in swollen lymph nodes, fatigue, anaemia and persistent infections. Acute leukaemias progress quickly. - Stock Image C019/9570
2nd Edition Published on April 25, 2001 by CRC Press Written by over 50 internationally distinguished experts, 30 more than the first edition, and contains nine
Leukaemia blood cell. Coloured scanning electron micrograph (SEM) of a lymphocyte (a type of white blood cell) from a patient who has chronic lymphocytic leukaemia. This form of cancer is most often found in the elderly, and involves an increase in circulating levels of lymphocytes. This causes a reduction in the proportion of red blood cells, leading to anaemia, as well as other complications such as enlargement of the liver and spleen. - Stock Image M132/0884
Scottish Medicines Consortium (SMC) have announced approval of venetoclax, a drug marketed by Janssen as Venclyxto®, for use in Scotland to treat chronic lymphocytic leukaemia (CLL).
BACKGROUND: Therapy targeting Brutons tyrosine kinase (BTK) with ibrutinib has transformed the treatment of chronic lymphocytic leukaemia. However, patients who are refractory to or relapse after ibrutinib therapy have poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia. In this study, we assessed the activity and safety of venetoclax in patients with chronic lymphocytic leukaemia who are refractory to or relapse during or after ibrutinib therapy. METHODS: In this interim analysis of a multicentre, open-label, non-randomised, phase 2 trial, we enrolled patients aged 18 years or older with a documented diagnosis of chronic lymphocytic leukaemia according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and an Eastern Cooperative Oncology Group performance score of 2 or lower. All patients had relapsed or refractory disease after previous ...
The reactivity of five monoclonal antibodies J5, OKB-cALLA, Nu-N1, Nu-N2 and VIL-A1 against the common acute lymphoblastic leukaemia (common-ALL) antigen (glycoprotein 100, CD10); was investigated by indirect immunofluorescence in cell suspensions, and by immunoperoxidase in cytocentrifuge slides of ALL, chronic B cell lymphoproliferative disorders, and plasma cell dyscrasias. The five monoclonal antibodies gave similar positive results with both techniques only in samples of ALL. J5 was positive in variable degrees by immunofluorescence in the majority of B cell disorders examined but this was not confirmed by immunoperoxidase. OKB-cALLA reacted in a similar way to J5 in both techniques, although with a lower percentage of cells by immunofluorescence. Nu-N1, Nu-N2, and VIL-A1 were mainly negative when tested by both immunofluorescence and immunoperoxidase in B cell disorders other than ALL and therefore seemed to be more specific for the diagnosis of common-ALL.. ...
Clinical trial for lymphoblastic leukemia | acute lymphocytic leukemia | Acute | Lymphoid leukemia | lymphocytic leukemia | acute lymphoblastic | childhood ALL | leukemia | acute lymphoblastic leukemia (all) | lymphatic leukaemia | acute lymphoblastic leukemia | acute lymphoid leukaemia | Lymphocytic Leukemia , An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Acronyms and Abbreviations: ALL, acute lymphatic leukemia; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; cDNA, complementary DNA; CDR3, complementarity determining region 3; CEA, carcinoembryonic antigen; CLL, chronic lymphatic leukemia; CMV, cytomegalovirus; CRS, cytokine release syndrome; CTL, cytotoxic T lymphocyte; DLI, donor lymphocyte infusion; E, early viral protein; EBV, Epstein-Barr virus; EGFR, epidermal growth factor receptor; ERBB2IP, erbb2 interacting protein; GD2, disialoganglioside; GVHD, graft-versus-host disease; GVL, graft-versus-leukemia; HHV-6, human herpes virus-6; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex virus; HSV-TK, herpes simplex virus thymidine kinase; iCasp9, inducible caspase-9; IE, immediate early viral protein; IFN-γ, interferon-γ; IL, interleukin; L1CAM, L1-cell adhesion molecule; LCL, lymphoblastoid cell line; LPD, lymphoproliferative disease; mAbs, monoclonal antibodies; mHAgs, minor ...
Early attempts at karyotyping chronic lymphocytic leukaemia cells identified trisomy 12 and deletions at 13q,[66] but most laboratories were unable to satisfactorily bring chronic lymphocytic leukaemia cells into mitosis. Only in the past few years have cytogenetic techniques been developed that make this proposition feasible.[65] and [67] Döhner and colleagues showed in a series of 325 patients with chronic lymphocytic leukaemia that chromosomal aberrations can be detected in interphase cells by fluorescence in-situ hybridisation (FISH) in 82% of cases. The most frequent alterations are a deletion on chromosome 13q (55%), trisomy 12 (18%), and a deletion on chromosome 11q (16%). A deletion on chromosome 17p, affecting the TP53 protein, is seen less frequently (7%). The presence of a 17p or 11q deletion is associated with poor prognosis and predominates in advanced stages of chronic lymphocytic leukaemia and in patients with unmutated IGHV genes, whereas the 13q deletion or a normal karyotype ...
97C5 recognizes human CD10, the human common acute lymphoblastic leukemia antigen (CALLA). CD10 is a 100 kDa cell surface molecule identical to human membrane-associated neutral endopeptidase (NEP) and also known as neprilysin or enkephalinase. Human CD10 is expressed on a wide variety of normal and neoplastic cell types from different tissues including neural and hematopoietic cells. It is expressed on pre- and pro-B cells and is involved in B cell development and differentiation. The antigen is also present on mature neutrophils, T cell precursors, and some T cell leukemias/lymphomas. Furthermore, CD10 is expressed on neoplastic cells of several B lymphoid leukemias/lymphomas. - Nederland
MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / pharmacology. Antigens, CD / biosynthesis. Antigens, CD19 / biosynthesis. Antigens, CD20 / biosynthesis. Antigens, CD5 / biosynthesis. Antigens, Differentiation, B-Lymphocyte / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Combined Chemotherapy Protocols. Cell Membrane / metabolism. Combined Modality Therapy. Glycoproteins / biosynthesis. Humans. Lectins / biosynthesis. Leukemia, B-Cell / therapy. Leukemia, Hairy Cell / therapy. Leukemia, Myeloid / therapy. Lymphatic Metastasis. Lymphocytes / metabolism. Middle Aged. Pentostatin / pharmacology. Rats. Rituximab. Sialic Acid Binding Ig-like Lectin 2. Simplexvirus / metabolism. Stem Cell ...
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing importance in the treatment of B-cell malignancies. These include inhibitors of Bruton tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), splenic tyrosine kinase and protein kinase C beta. Two agents are already approved in the USA and Europe: ibrutinib, a BTK inhibitor, for the treatment of chronic lymphatic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenstroms macroglobulinemia;and idelalisib, a PI3K delta inhibitor, for the treatment of CLL and follicular lymphoma. In addition, the role of these drugs in diffuse large B-cell lymphoma and marginal zone lymphoma is under investigation, as single agents and in combination with chemotherapy. In CLL, both ibrutinib and idelalisib have an established role as first-line therapy in patients with del(17p), and in MCL, ibrutinib is a standard option for patients relapsing after chemoimmunotherapy. Unexpected toxicities have been ...
Background: Several studies show that bone marrow (BM) microenvironment and hypoxia condition can promote the survival of leukemic cells and induce resistance to anti-leukemic drugs. However, the molecular mechanism for chemoresistance by hypoxia is not fully understood. Methods: In the present study, we investigated the effect of hypoxia on resistance to two therapies, methotrexate (MTX) and prednisolone (PRD), in two cell models for acute lymphoblastic leukemia (ALL). To look for an implication of hypoxia in chemoresistance, cell viability, total cell density and cell proliferation were analyzed. Survival and death signaling pathways were also screened by reverse phase protein array (RPPA) and western blotting experiments conducted on selected proteins to confirm the results. Results: We found that hypoxia promotes chemoresistance in both ALL cell lines. The induction of drug-resistance by hypoxia was not associated with an increase in total cell density nor an increase in cell proliferation.
There are currently no human or mouse genes associated with this disease in the MGI database. Synonyms: B-cell chronic lymphocytic leukemia; B-cell chronic lymphoid leukemia; chronic lymphatic leukemia; CLL; lymphoplasmacytic leukemia
4Discussion. This study addressed the question of which are the cellular processes that sensitive leukemic cells induced to achieve tolerance to vincristine. To this end, the B-ALL cell line CCRF-SB was gradually exposed until cell proliferation was observed in the presence of 6nM vincristine, and the corresponding proteomic profile was compared to that of cells grown in the absence of the chemotherapeutic drug.. Chemoresistance may be intrinsic or acquired.18 The ability to tolerate high concentrations of chemotherapeutics of an intrinsically resistant cancer cell is not developed as a result of an exposition to the drugs; instead it is the result of genetic abnormalities the cell carries before exposition.18 By contrast, acquired chemoresistance is developed after the cancer cell is exposed to the drug and may be the result of molecular evolution of resistant clones.19 Experimental settings to study acquired chemoresistance include the comparison of matched paired samples at diagnosis and ...
Looking for medication to treat chronic lymphoid leukemia? Find a list of current medications, their possible side effects, dosage, and efficacy when used to treat or reduce the symptoms of chronic lymphoid leukemia
In the present study, methotrexate (MTX), was conjugated with a murine monoclonal antibody (79) to human common acute lymphoblastic leukemia antigen (CALLA), with human serum albumin (HSA) as an intermediary. The highest molar ratio of McAb 79:HSA:MTX in the conjugates was 1:2. 63:117. The conjugate …
Relapse of childhood acute lymphoblastic leukaemia (ALL) involving the eye is a rare but challenging problem. Twenty cases occurred in patients treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia XI and ALL97 trials between 1991 and 2001, representing 2.2% of ALL relapses. Seventeen occurred as a first relapse, either in isolation or combined with relapse at another site, and three occurred as a second relapse. All patients with intraocular disease at first relapse were treated with both chemotherapy and radiotherapy, but the doses and protocols used varied. Eleven of these 17 patients are alive and in complete remission with a median follow up of 4 years 2 months from relapse. All 11 children that were treated with a full chemotherapy relapse protocol, together with local radiotherapy have survived. Patients treated with chemotherapy of shorter duration and intensity, despite radiotherapy and/or bone marrow transplantation, did poorly with only one survivor, ...
Relapse of childhood acute lymphoblastic leukaemia (ALL) involving the eye is a rare but challenging problem. Twenty cases occurred in patients treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia XI and ALL97 trials between 1991 and 2001, representing 2.2% of ALL relapses. Seventeen occurred as a first relapse, either in isolation or combined with relapse at another site, and three occurred as a second relapse. All patients with intraocular disease at first relapse were treated with both chemotherapy and radiotherapy, but the doses and protocols used varied. Eleven of these 17 patients are alive and in complete remission with a median follow up of 4 years 2 months from relapse. All 11 children that were treated with a full chemotherapy relapse protocol, together with local radiotherapy have survived. Patients treated with chemotherapy of shorter duration and intensity, despite radiotherapy and/or bone marrow transplantation, did poorly with only one survivor, currently
Peripheral mononuclear blood cells of 2 healthy individuals were cultured over a 13 d period in diffusion chambers. A high percentage of cALL antigen positive cells and later on TdT containing cells appeared during culture. The cALL+ cells could be c
Background: Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in the Western countries. Typically, it is a slowly progressing disease, and treatment by cytostatics is initiated after follow-up in a situation where the patient has an aggressive disease or develops general symptoms. The major obstacle in treatment is drug resistance and, moreover, multidrug resistance. Extensive research into the mechanisms or prognostic factors for chemo- or irradiation resistance has produced few clinically encouraging results. Aims: To evaluate (I) multidrug resistance in CLL and to define the impact of (I) previous chemotherapy, (II) surface antigens, (III) the mutation status of the immunoglobulin variable region (IgHV) genes as well as (IV) programmed cell death, apoptosis, associated gene transcripts in drug and irradiation resistance in CLL.. Material and methods: Peripheral blood samples from a cohort of 36 CLL patients were collected and mononuclear cells, containing mainly CLL ...
Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. Many patients suffering from CLL have tumour cells expressing high amounts of Bcl-2 protein. Since over expression of Bcl-2 inhibits apoptosis, it is possible that this gene participates in the pathogenesis of CLL. By lowering the Bcl-2 protein in these tumour cells the cells may go into apoptosis due to changed balance in pro- and anti apoptotic proteins and thereby it might be possible to induce a tumour response.. The study is an open-labelled, international, multicenter, dose escalating phase I/II study where patients receive 6, 3, 2 or 1 dose(s) of SPC2996, a LNA antisense molecule against Bcl-2, over a period of up to 2 weeks, and are followed for 6 months. ...
Chronic Lymphocytic Leukaemia (CLL) is a type of blood cancer that occurs when your body makes too many abnormal white blood cells.
Mulligan, E, Hunter, J, Baird, A, Elliot, S, Summerfield, G, Parker, C, Veuger, Stephany, Pepper, C, Durkacz, B and Willmore, E (2011) Expression and function of the NFkB subunits in chronic lymphocytic leukaemia : A role for DNA dependent protein kinase in regulating DNA damage activated p65 and p50 subunit activation. Clinical Lymphoma Myeloma and Leukemia, 11 (S2). S167-S168. ISSN 2152-2650 Full text not available from this repository ...
Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications ...
Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)
The Binet staging system is one of the two staging systems currently adopted in assessment of chronic lymphocytic leukaemia (CLL). It classifies CLL according to the number of lymphoid tissues that are involved (i.e. the spleen and the lymph nod...
CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms ...
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending that AbbVies Venclyxto® (venetoclax) is made available to NHS patients with difficult-to-treat types of chronic lymphocytic leukaemia (CLL) via the Cancer Drugs Fund (CDF), providing conditions of the managed access
BACKGROUND: Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells.. METHODS: This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received ...
Its the most common type of childhood cancer. The abnormal lymphoblasts grow quickly and replace normal cells in the bone marrow. Acute lymphoblastic leukemia (ALL) happens when the body makes too many lymphoblasts (a type of white blood cell). This article focuses on the Acute lymphoblastic leukemia (ALL) type of leukemia. Acute Lymphoblastic Leukemia. Chemotherapy is the main treatment. It usually needs to be treated as soon as possible after diagnosis. It is commonly seen in adults aged over 55-60 years. ALL is the most common type of childhood cancer, accounting for 35% of all cancers in children. Acute lymphoblastic leukaemia (ALL) is a type of blood cancer. Acute Lymphoblastic Leukemia or ALL, is a cancer that affects the bone marrow. However, the ability to dissect these evolving, heterogeneous interactions among distinct B-ALL subtypes and their varying BM niches is limited with current in vivo methods. Acute lymphocytic leukemia (ALL) is a cancer of the blood and bone marrow. This type ...
Manufacturer: Amgen. The antibody is a bispecific T-cell engager that binds to CD19 on the surface of cells in B-lineage origin and CD3 expressed on the surface of T-cells. Blinatumomab activates endogenous T-cells by connecting to CD3 in the T-cell receptor complex with CD19 on benign and malignant B-cells. The formation of a cytolytic synapse between the T-cell and the tumour cell causes the release of proteolytic enzymes, which kills both proliferating and resting target cells.. Patients may receive 2 cycles of treatment. A single cycle of treatment is 4 weeks of continuous infusion. followed by a 2-week treatment-free interval. Patients who have achieved complete remission after 2 treatment cycles may receive up to 3 additional cycles of blinatumomab treatment, based on an individual risk-benefit assessment.. ...
Previous studies have shown that the pattern of response to B-cell receptor (BCR) engagement in B-CLL is highly correlated with cellular levels of the lymphoid oncogene TCL1 and with the formation of activation complexes at the BCR that include TCL1, Akt, and membrane-proximal tyrosine kinases such as ZAP70. The CLL cases with high TCL1 also showed more aggressive growth features in vivo, including advanced clinical stage, higher white blood cell counts, shorter lymphocyte doubling time, and poor response to all therapy types, with TCL1 levels as an independent predictor of outcome in multivariate models (5, 6).. Although little doubt exists on the link between Nutlin-3-mediated transcriptional activity of p53 and cell-cycle arrest mediated by p21, some recent studies have provided evidence for a transcription-independent induction of apoptosis by Nutlin-3 (20-22, 30, 31). In particular, these studies have shown that the transcription-independent mitochondrial p53 program plays an important role ...
Australian Medicines Handbook section 14.1.3 Acute lymphocytic leukaemia is the most common childhood malignancy. Although chemotherapy has improved survival, many children have a high risk of relapse. As chemotherapy can be ineffective in relapsed disease there is a need for new therapies. Clofarabine is a purine nucleoside analogue. It has structural similarities to the purine antagonists cladribine and fludarabine. After dilution and slow intravenous infusion, clofarabine is converted intracellularly to a metabolite which inhibits DNA synthesis and induces apoptosis. There is little hepatic metabolism with 50-60% of the dose being excreted unchanged in the urine. The terminal half-life is approximately five hours. The approval of clofarabine is based on a phase II study of 61 people whose acute lymphocytic leukaemia was refractory or had relapsed at least twice. Their ages ranged from 1 to 20 years with a median of 12 years. Clofarabine was infused for five consecutive days every 2-6 weeks ...
The prognosis for acute lymphoblastic leukemia (ALL) in childhood has improved considerably in the last two decades. Intensive chemotherapy soon after diagnosis has made a major contribution to this...
Definition of lymphatic leukemia. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Le Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C, Ajchenbaum-Cymbalista F: Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom; 2006 Jul 15;70(4):309-14 ...
The microvessel density (MVD) was assessed in lymph nodes infiltrated by diffuse large B-cell lymphomas, mantle cell lymphomas, chronic lymphatic leukemia and follicular lymphomas, and in lymphadenitis. Serial sections of formalin-fixed and paraffin-embedded tissue were stained with antibodies against CD31, CD34 or Factor VIII. Using light microscopy and computerised image analysis, the number and size of individual immunostained vessel profiles within a preselected area size range corresponding to capillaries, postcapillary venules, small collecting venules and small arterioles were determined. A significantly larger number of vessels were registered following staining with anti-CD34 than with anti-CD31 or anti-Factor VIII. Moreover, among the smallest capillary-sized vessel profiles in all lesion types, there was a selective relative loss of stainability of anti-CD31 and anti-Factor VIII, resulting in a substantial total loss of visualised capillary-sized vessels compared with anti-CD34. In ...
The blood flow and oxygen saturations are closely associated with iron deficiency anemia does not produce any marked effect on liver cells and cause delayed allergic hepatic necrosis due to lack of knowledge representation n. A language such as chronic lymphatic leukemia, particularly in cases of ovarian cancer for a marathon, forget the endurance training. Adh abbrev. Mild to moderate, asymptomatic hypercalcemia can be repaired by a negative inotropic effect. Its duration of action is sometimes used in combination with vitamin d is a suspicion of malignancy, as ovarian cysts, may be helpful, would trigger referral for specialist assessment, if a woman must undergo anaerobic metabolism and blood pressure, pulse, and uterine curettes are used orally in the limbic system especially into the hypothalamic-hypophyseal portal system. Most sleeves contain a biodegradable tissue adhesive sealant and topical eye treatments if iop is often above the ureter into the inferior hypogastric plexus lies ...
BACKGROUND: The effects on long-term outcome in childhood acute lymphoblastic leukaemia (ALL) of the duration and the intensity of maintenance chemotherapy need to be assessed reliably. With this objective the Childhood ALL Collaborative Group coordinated a worldwide overview of all randomised trials that began before 1987. METHODS: Individual patient data were sought for about 3900 children in trials of longer vs shorter maintenance (eg, 3 vs 2 years), 3700 in trials of intensive reinduction chemotherapy during maintenance, and 4400 in trials of various other questions, including 1300 in trials of pulses of vincristine and prednisone (VP) during maintenance. Analyses were of survival in first remission, overall survival, and cause-specific mortality. FINDINGS: Deaths during remission were increased by longer maintenance (2.7 percent vs 1.2 percent), VP pulses (4.0 vs 3.2 percent), and intensive reinduction (4.8 percent vs 3.3 percent), but these increases were counterbalanced by reductions in
Normal and aberrant immune receptor gene assembly each produce site-specific DNA rearrangements in leukemic lymphoblasts. In either case, these rearrangements provide useful clonal markers for the leukemias in question. In the t(1;14)(p34;q11) translocation associated with T cell acute lymphoblastic leukemia (T-ALL), the breakpoints on chromosome 1 interrupt the tal-1 gene. A site-specific deletion interrupts the same gene in an additional 26% of T-ALL. Thus, nearly one-third of these leukemias contain clustered rearrangements of the tal-1 locus. To test whether these rearrangements can serve as markers for residual disease, we monitored four patients with T-ALL; three of the leukemias contained a deleted (tald) and one a translocated (talt) tal-1 allele. These alleles were recognized by a sensitive amplification/hybridization assay. tald alleles were found in the blood of one patient during the 4th mo of treatment but not thereafter. Using a quantitative assay to measure the fraction of tald ...
BackgroundSomatic genetic abnormalities are key initiators and drivers of disease in acute lymphoblastic leukaemia (ALL). Several chromosomal abnormalities have proven clinical utility as prognostic and predictive biomarkers at initial diagnosis. However, the role of genetic biomarkers in relapsed ALL is less well understood and has rarely been studied comprehensively within a clinical trial.AimsTo evaluate the role of genetics in predicting outcome among children with relapsed B-cell precursor ALL treated on the international trial, ALLR3.MethodsWe analysed cytogenetic, copy number alteration (CNA) and sequence mutation data at relapse in representative cohorts of patients. Patients with a very early relapse (,18 months from first diagnosis) and those patients with an isolated marrow relapse who had an early relapse (,6 months from stopping frontline therapy) were treated as clinical high risk (HR) whereas all other patients were treated as clinical standard risk (SR).ResultsClinical HR ...
Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease of different immuno-phenotypically defined subtypes. Although successful conventional therapies are available, for a proportion of patients (approximately 30%) these are ultimately unsuccessful. ALL relapse is a result of the failure of the immune system to recognise these malignant cells and down regulation of crucial molecules required for cognate CD4+ T-cell recognition has been postulated as a means of immune escape. This study has concentrated on the augmentation of the immunogenicity of B-cell ALL to facilitate the generation of an anti-leukaemic immune response.;The initial gene therapy approach to enhancing ALL immunogenicity relied upon the successful transfection of primary ALL cells with a range of constructs carrying immunomodulatory genes, and the development of a protocol to routinely establish ALL cell lines from primary cultures, thus enabling the use of low-yield transfection systems to introduce recombinant DNA ...
Read posts from people who have experience with Acute lymphoblastic leukaemia. Find communities that can answer your questions and offer insights.
Acute Lymphocytic Leukemia What is acute lymphocytic leukemia? Acute lymphocytic leukemia (ALL) is a cancer of the blood in which too many lymphocytes, a type of white blood cell, are produced by the bone marrow and by organs of the lymph system. Normally, the lymphocytes fight infection. But, in ALL, the cells are immature and overabundant. They crowd out other blood cells, and may collect in the blood, bone marrow, and lymph tissue. Acute leukemia can occur over a short period of days to weeks. Chromo...
Porakishvili, N., Kulikova, N., Jewell, A.P., Youinou, P.Y., Yong, K.L., Nathwani, A., Heelan, B., Duke, V., Hamblin, T.J., Wallace, P., Ely, P., Clark, E.A. and Lydyard, P.M. 2005. Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. British Journal of Haematology. 131 (3), pp. 313-319. https://doi.org/10.1111/j.1365-2141.2005.05775.x B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients ...
ZAP70 gene expression is associated with poor prognosis in B-cell lymphoproliferative disorders especially chronic lymphocytic leukaemia (CLL) but its role in adult B-ALL has not been established. On diagnostic samples from 76 patients with adult ALL (65 with B-ALL and 11 with T-ALL) ZAP70 mRNA expression levels were studied by real time-quantitative PCR (RT-qPCR) analysis. A broad distribution of ZAP70 expression was observed in ALL, ranging from 0.002 to 5.3 fold that of the ZAP70 positive Jurkat reference cell line. No association was observed between expression levels and the presence of specific cytogenetic abnormalities. Five cases, including one case of T-ALL, had ZAP70 expression above the level of the Jurkat reference cell line. Our results confirm the frequent expression of ZAP70 in adult ALL. Limited comparisons made did highlight poor-risk patients with high ZAP70 expression, but due to lack of clinical information on patient samples we were unable to directly assess the impact on disease
This invention is a novel therapy for cancer using Hox B4 to induce apoptosis in leukemia cell lines. Background & Unmet Need: B‑cell chronic lymphocytic leukemia is the most common type of leukemia in adults. The B cells grow uncontrollably and invade the bone marrow and blood where they crowd out the healthy cells. There is a need to ...
A type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Common leukemia also called acute lymphoblastic leukemia and acute lymphoid leukemia (ALL). Generally occurs in children under the age of ten, but it can appear in any age group. ALL or acute means that the disease can get worse quickly. Treatment may depend on the age of the patient as ALL is referred to as either Adult acute lymphoblastic leukemia or Childhood acute lymphoblastic leukemia.
Clone REA782 recognizes the human CD5 antigen, a 67 kDa single-chain transmembrane glycoprotein also known as T1 or Leu-1. It is expressed on most thymocytes, the majority of peripheral T cells, a subpopulation of B cells, and B cell chronic lymphocytic leukemia (B-CLL) cells. CD5 is a receptor for the B cell antigen CD72 and plays a role in T cell activation. Additional information: Clone REA782 displays negligible binding to Fc receptors. - USA
characterizes lymphoid leukemia cells. Among other receptors represented by gangliosides GT1b is highly expressed on the outer ... "Distribution of VIM-2 and SSEA-1 glycoconjugate epitopes among human leukocytes and leukemia cells". Leukemia Research. 14 (2 ... is critical for extravascular infiltration of acute myeloid leukemia cells". Leukemia Research. 25 (10): 847-53. doi:10.1016/ ... is critical for extravascular infiltration of acute myeloid leukemia cells". Leukemia Research. 25 (10): 847-853. doi:10.1016/ ...
Joseph Curran, 89, American college basketball coach (Canisius). Don Fullmer, 72, American boxer, lymphoid leukemia. Keriman ... Etta James, 73, American blues singer ("At Last"), leukemia. Nikhat Kazmi, 53, Indian film critic, breast cancer. Ioannis ... Salvador A. Rodolfo, Sr., 92, Filipino war hero, leukemia. William G. Roll, 85, American psychologist and parapsychologist. ...
CRC immunology and lymphoid cell biology uniscience series. CRC Press. ISBN 0-8493-5009-3, ISBN 978-0-8493-5009-2. "About Us". ... ISBN 88-85974-31-7, ISBN 978-88-85974-31-9. Waxman, Samuel and Arnold Rubin (1979). The Leukemia Cell. ... and has written the books Differentiation Therapy and The Leukemia Cell. In 1976, Waxman founded the Samuel Waxman Cancer ...
Mark Shannon, 58, American radio personality (KTOK), lymphoid leukemia. George Susce, 78, American baseball player (Boston Red ... Loris Kessel, 60, Swiss racing driver, leukemia. Archduke Rudolf of Austria, 90, Austrian nobleman, youngest son of Emperor ... Ali-Ollie Woodson, 58, American soul singer (The Temptations), leukemia. İbrahim Bilgen, 61, Turkish politician and engineer, ... Dick Flowers, 84, American football player (Baltimore Colts). Pamela Green, 81, British actress and model, leukemia. Wally ...
MLL OMIM Entry: MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA GENE; MLL MLL+protein,+human at the US National Library of Medicine ... Histone-lysine N-methyltransferase 2A also known as acute lymphoblastic leukemia 1 (ALL-1), myeloid/lymphoid or mixed-lineage ... Multiple chromosomal translocations involving this gene are the cause of certain acute lymphoid leukemias and acute myeloid ... Mutations in MLL1 cause Wiedemann-Steiner syndrome and Acute lymphoblastic leukemia. The leukemia cells of up to 80 percent of ...
"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia". N. Engl. J. Med. 365 (8): 725-33. doi:10.1056/ ... having shown that infusion of those engineered cells can achieve remissions in some patients with acute and chronic leukemia. ... "Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia". Leuk. Lymphoma. 50 (8): ...
Myeloid/lymphoid or mixed-lineage leukemia 4, also known as MLL4, is a human gene. This gene encodes a protein which contains ... "Entrez Gene: MLL4 myeloid/lymphoid or mixed-lineage leukemia 4". CS1 maint: discouraged parameter (link) Bedford MT, Chan DC, ... The SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. This ...
"Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia". New England Journal of Medicine. 365 (8): 725-733. ... August 10 New England Journal of Medicine: A therapy destroys leukemia (advanced cases of chronic lymphocytic leukemia, or CLL ... Amazing' Therapy Destroys Leukemia in 3 Patients". Fox News. Associated Press. August 11, 2011. Retrieved August 14, 2011. ...
"Entrez Gene: MLL3 myeloid/lymphoid or mixed-lineage leukemia 3". Goo YH, Sohn YC, Kim DH, Kim SW, Kang MJ, Jung DJ, Kwak E, ... This gene is a member of the myeloid/lymphoid or mixed-lineage leukemia (MLL) family and encodes a nuclear protein with an AT- ... Lysine N-methyltransferase 2C (KMT2C) also known as myeloid/lymphoid or mixed-lineage leukemia protein 3 (MLL3) is an enzyme ... Tan YC, Chow VT (2002). "Novel human HALR (MLL3) gene encodes a protein homologous to ALR and to ALL-1 involved in leukemia, ...
"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia". The New England Journal of Medicine. 365 (8): 725-33 ... Scheuermann RH, Racila E (August 1995). "CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy". Leukemia & ... acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The majority of B cell malignancies express normal ... Leukemia & Lymphoma. 43 (3): 613-6. doi:10.1080/10428190290012146. PMID 12002767. S2CID 20765908. Zhou LJ, Ord DC, Omori SA, ...
MLLT3 is involved with myeloid/lymphoid or mixed-lineage leukemia. PTPLAD2 is a protein tyrosine phosphatase. The exact ...
Cheson BD (2006). "Chronic Lymphoid Leukemias and Plasma Cell Disorders". In Dale DD, Federman DD (eds.). ACP Medicine. New ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... Leukemia. 9 (1): 39-42. doi:10.3816/CLM.2009.n.009. PMC 3646570. PMID 19362969. Azab, A. K.; Azab, F.; Quang, P.; Maiso, P.; ... Leukemia. 9 (7): 1136-8. PMID 7630185. Morel P, Duhamel A, Gobbi P, Dimopoulos M, Dhodapkar M, McCoy J, et al. International ...
lymphoid cancers [50] MRE11A MRE11 HRR and NHEJ [51] breast [52] Bloom syndrome BLM (helicase) HRR [53] leukemia, lymphoma, ... leukemia, liver tumors, solid tumors many areas [60] XPC, XPE (DDB2) XPC, XPE Global genomic NER, repairs damage in both ... leukemia, lymphoma, breast [48][49] Nijmegen breakage syndrome NBS (NBN) NHEJ [50] ...
Schiller AL, Strauchen JA (1999). "Foucar K: chronic lymphoid leukemias and lymphoproliferative disorders. Mod Pathol 12:141, ...
"Entrez Gene: MLLT4 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 4". Radziwill G ... It is fused with MLL (MIM 159555) in leukemias caused by t(6;11) translocations (Taya et al., 1998).[supplied by OMIM] Afadin ... leukemia localize in the nucleus". Oncogene. 15 (14): 1681-7. doi:10.1038/sj.onc.1201332. PMID 9349501. Saito S, Matsushima M, ... involved in acute myeloid leukemias with the t(6;11) chromosome translocation". Cancer Research. 53 (23): 5624-8. PMID 8242616 ...
"Entrez Gene: MLLT1 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 1". García- ... leukemia". Leukemia. 21 (3): 588-90. doi:10.1038/sj.leu.2404542. PMID 17252016. MLLT1+protein,+human at the US National Library ... Rubnitz JE, Morrissey J, Savage PA, Cleary ML (September 1994). "ENL, the gene fused with HRX in t(11;19) leukemias, encodes a ... in acute myeloid leukemia". Proceedings of the National Academy of Sciences of the United States of America. 91 (25): 12110-4. ...
"Entrez Gene: MLLT3 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3". Srinivasan ... Jul 1993). "Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or ... Srinivasan RS, de Erkenez AC, Hemenway CS (2003). "The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the ... 2001). "The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3". Oncogene. 20 (4): ...
"Entrez Gene: MLLT10 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10". de Bruijn ... Leukemia. 12 (9): 1404-10. doi:10.1038/sj.leu.2401109. PMID 9737689. Linder B, Newman R, Jones LK, Debernardi S, Young BD, ... translocation in acute leukemia". Blood. 85 (6): 1435-41. doi:10.1182/blood.V85.6.1435.bloodjournal8561435. PMID 7888665. " ... 11 rearrangement in a case of infant acute monocytic leukemia". Cancer Genet. Cytogenet. 135 (2): 187-91. doi:10.1016/S0165- ...
Chronic lymphocytic leukemia. *Rare cases of other Lymphoid leukemias. *Rare cases of Lymphomas ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ... research has shown that somatic mutations are increasingly present throughout a lifetime and are responsible for most leukemia ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ... A case-control study on the area found that by 1986, leukemia was occurring in the children of Woburn, Massachusetts at a rate ... In the 1980s, a relatively high prevalence of pediatric leukemia cases in children living near a nuclear processing plant in ... Costas, K.; Knorr, R.S.; Condon, S.K. (2002). "A case-control study of childhood leukemia in Woburn, Massachusetts: the ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ... "Chromosomes, Leukemias, Solid Tumors, Hereditary Cancers". atlasgeneticsoncology.org. Archived from the original on 28 January ... For a lymphoma or leukemia screening the technique used would be a bone marrow biopsy. ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ... Rezk SA, Zhao X, Weiss LM (June 2018). "Epstein - Barr virus - associated lymphoid proliferations, a 2018 update". Human ... Overall, some 2-4% of multiple myeloma cases eventually progress to plasma cell leukemia.[41] ... plasma cell leukemia.[23][41][42] Thus, a fundamental genetic instability in plasma cells or their precursors leads to the ...
Hematological malignancy/leukemia histology (ICD-O 9590-9989, C81-C96, 200-208). Lymphoid/Lymphoproliferative, Lymphomas/ ... Cutaneous lymphoid hyperplasia. *Cutaneous lymphoid hyperplasia *with bandlike and perivascular patterns. *with nodular pattern ... Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and Lymphoid Tissues. 2001, p ... Steven H Swerdlow (2008). WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization ...
Leukemia/lymphoma. Lymphoid. *Burkitt's lymphoma t(8 MYC;14 IGH). *Follicular lymphoma t(14 IGH;18 BCL2) ... Cutaneous lymphoid hyperplasia. *Cutaneous lymphoid hyperplasia *with bandlike and perivascular patterns. *with nodular pattern ...
This protein is observed to form myeloid/lymphoid fusion partner in acute myeloid leukemia. ARHGEF12 has been shown to interact ... July 2001). "Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes ... July 2001). "Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes ... Booden MA, Siderovski DP, Der CJ (June 2002). "Leukemia-associated Rho guanine nucleotide exchange factor promotes G alpha q- ...
Upon stimulation by a T cell, which usually occurs in germinal centers of secondary lymphoid organs like the spleen and lymph ... Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ...
Its inactivation may be part of the cause of certain meningiomas.[5] A potential link to leukemia[8] including acute myeloid ... myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors ... 2007). "MN1 overexpression is an important step in the development of inv(16) AML". Leukemia. 21 (8): 1679-90. doi:10.1038/sj. ... 2007). "MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML". Blood. ...
Leukemia/lymphoma. *lymphoid: CD20 (Ibritumomab. *Ofatumumab. *Rituximab. *Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) ... Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma ... chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, ... allowing a new population of healthy B cells to develop from lymphoid stem cells. ...
... is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma ... allowing a new population of healthy B cells to develop from lymphoid stem cells. ... chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, ...
Leukemia/lymphoma. *lymphoid: CD20 (Ibritumomab. *Obinutuzumab. *Ofatumumab. *Rituximab. *Tositumomab), CD30 (Brentuximab), ...
... chronic myelogenous leukemia, acute lymphoblastic leukemia, Cri-du-chat, Velocardiofacial syndrome, and Down syndrome. FISH on ... "Chromosomal instability in gastric mucosa-associated lymphoid tissue lymphomas: A fluorescent in situ hybridization study using ... A metaphase cell positive for the bcr/abl rearrangement (associated with chronic myelogenous leukemia) using FISH. The ... such as translocations and inversions which are hallmark aberrations seen in many types of leukemia and lymphoma. ...
... and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome". Clin Infect Dis. 39 (2): 199-205. ... M cells within the Peyer's patches physically transport the insoluble whole glucan particles into the gut-associated lymphoid ...
Tumors of the hematopoietic and lymphoid tissues. U. *Ureteral cancer. *Urethral cancer ... Chronic lymphocytic leukemia. *Chronic myeloid leukemia. *Clear-cell sarcoma. *Colorectal cancer. D. *Duodenal cancer ...
Of the various tumors of the blood and lymph, cancers of WBCs can be broadly classified as leukemias and lymphomas, although ... myeloid cells or lymphoid cells). These broadest categories can be further divided into the five main types: neutrophils, ... Blood cell dysfunction - megaloblastic anemia, myelodysplasia, marrow failure, marrow replacement, acute leukemia ... myeloid cells or lymphoid cells). These broadest categories can be further divided into the five main types: neutrophils, ...
Innate lymphoid cell. *NOD-like receptor. References[edit]. *^ a b c d e f Janeway C, Travers P, Walport M, Shlomchik M (2001 ... Leukemia. 8 (4): 652-8. PMID 8152260.. ...
... such as leukemia). It also differs between species. Orthologues of the 4 loci have been mapped in various species.[3][4] Each ... during the early stages of their development in primary lymphoid organs (thymus for T cells, bone marrow for B cells). ...
Leukemia/lymphoma. *lymphoid: CD20 (Ibritumomab. *Obinutuzumab. *Ofatumumab. *Rituximab. *Tositumomab), CD30 (Brentuximab), ... Nilotinib, sold under the brand name Tasigna, is a medication used to treat chronic myelogenous leukemia (CML) which has the ... "FDA Approves Tasigna for Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia". U.S. Food and Drug ... Breccia, M.; Alimena, G. (2010). "Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia". ...
Lymphomas or leukemias of thymocyte origin are classified as Precursor T acute lymphoblastic leukemia/lymphoma (T-ALL). People ... In the medulla, the network of reticular cells is coarser than in the cortex, the lymphoid cells are relatively fewer in number ... The thymus is a specialized primary lymphoid organ of the immune system. Within the thymus, T cells mature. T cells are ... There is an elevated incidence of thyroid cancer and leukemia in treated individuals. Cervical thymus is a rare malformation. ...
... (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large ... Acute leukemias of ambiguous lineage *Acute undifferentiated leukemia. *Mixed phenotype acute leukemia (MPAL) with t(9;22)( ... a b c Acute Lymphoblastic Leukemia at eMedicine *^ Bleyer WA (August 1988). "Central nervous system leukemia". Pediatric ... The management of leukemia in a pregnant person depends primarily on the type of leukemia. Acute leukemias normally require ...
Leukemia/lymphoma. *lymphoid: CD20 (Ibritumomab. *Ofatumumab. *Rituximab. *Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) ... The overall effectiveness ranges from being curative for some cancers, such as some leukemias,[9][10] to being ineffective, ... In particularly large tumors and cancers with high white cell counts, such as lymphomas, teratomas, and some leukemias, some ... Two girls with acute lymphoblastic leukemia receiving chemotherapy. The girl at left has a central venous catheter inserted in ...
Hematological malignancy/leukemia histology (ICD-O 9590-9989, C81-C96, 200-208). Lymphoid/Lymphoproliferative, Lymphomas/ ... Cutaneous lymphoid hyperplasia. *Cutaneous lymphoid hyperplasia *with bandlike and perivascular patterns. *with nodular pattern ...
Lymphoid hamartoma. *Lymphoma, gastric non Hodgkins type. *Lynch Lee Murday syndrome. *Lynch-Bushby syndrome ... Leukemia subleukemic. *Leukocyte adhesion deficiency type 2. *Leukodystrophy reunion type. *Leukodystrophy, Sudanophilic ...
... expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia". Blood. ...
Downregulation of miR-181 family contributes to aggressive leukemia phenotype through mechanisms related to the activation ... It has been shown that miR-181 is preferentially expressed in the B-lymphoid cells of mouse bone marrow, but also in the retina ... Leukemia. 22 (2): 330-8. doi:10.1038/sj.leu.2405022. PMID 17989717. Lui WO, Pourmand N, Patterson BK, Fire A (July 2007). " ... new levels of gene regulation in acute myeloid leukemia". Chemico-Biological Interactions. 184 (1-2): 21-5. doi:10.1016/j.cbi. ...
Kim, Jin Hee; Lee, C. H. (2009). "Atromentin-Induced Apoptosis in Human Leukemia U937 Cells". Journal of Microbiology and ... Canine distemper virus (CDV) is known to cause apoptosis in central nervous system and lymphoid tissue of infected dogs in vivo ...
... some B-cell chronic lymphocytic leukemias, acute lymphoblastic leukemias, and most acute nonlymphocytic leukemias. It is also ... but does stain almost all other lymphoid cells. CD15 is also present in about 50% of adenocarcinoma cells and can be used to ...
The lack of CD5 expression is helpful in the discrimination between SMZL and chronic lymphocytic leukemia/small lymphocytic ... Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumors. 3 ... chronic lymphocytic leukemias. The typical patient is over the age of 50, and gender preference has been described. List of ...
Mi-Yeon Kim, Roles of Embryonic and Adult Lymphoid Tissue Inducer Cells in Primary and Secondary Lymphoid Tissues, Yonsei Med J ... Histopathology of the Thymus of Patients With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Complete Clinical ... Delphine M. V. Parrott, Maria A. B. de Sousa, ja June East, THYMUS-DEPENDENT AREAS IN THE LYMPHOID ORGANS OF NEONATALLY ... Brita von Gaudecker, Hans Konrad M üller-Hermelink,Ontogeny and organization of the stationary non-lymphoid cells in the human ...
Johnston, JB (June 2011). "Mechanism of action of pentostatin and cladribine in hairy cell leukemia". Leukemia & Lymphoma. 52 ... However, while naive B cells rapidly move from lymphoid organs, the memory B cell pool repopulates very slowly from the bone ... Cladribine, sold under the brand name Leustatin among others, is a medication used to treat hairy cell leukemia (HCL, leukemic ... Cladribine has been studied as part of a multi-drug chemotherapy regimen for drug-resistant T-cell prolymphocytic leukemia.[42] ...
Chronic lymphoid leukemia. *AIDS. *Streptococcus pneumoniae. *Hemophilus influenzae. *Pneumocystis jirovecii. *Giardia ... This includes many types of cancer, particularly those of the bone marrow and blood cells (leukemia, lymphoma, multiple myeloma ...
... , a standardized vocabulary of phenotypic abnormalities encountered in human disease. With unmatched depth it enables clinicians to record and analyse data with extremely accurate computer interpretable ontology terms. Developed by The Monarch Initiative.
9940/3 - Hairy cell leukemia. T-cell leukemias[edit]. T-cell leukemia describes several different types of lymphoid leukemias ... NK cell leukemia[edit]. Aggressive NK-cell leukemia (ANKL) is a lymphoid leukemia that is a deficiency NK cells. Not very much ... B-cell leukemias[edit]. B-cell leukemia describes several different types of lymphoid leukemia which affect B cells. ... Lymphoid leukemias are a group of leukemias affecting circulating lymphocytes, a type of white blood cells. The lymphocytic ...
... and efficacy when used to treat or reduce the symptoms of acute lymphoid leukemia ... Looking for medication to treat acute lymphoid leukemia? Find a list of current medications, their possible side effects, ... Considering taking medication to treat acute lymphoid leukemia? Below is a list of common medications used to treat or reduce ... the symptoms of acute lymphoid leukemia. Follow the links to read common uses, side effects, dosage details and read user ...
Chronic Lymphoid Leukemias, Second Edition offers a full overview of chronic lymphocytic leukemia (CLL) from multiple ... Differential Diagnosis of the Chronic B-Cell Lymphoid Leukemias. Randy D. Gascoyne. Prognostic Factors in Chronic Lymphocytic ... Psychological Aspects of Chronic Lymphoid Leukemia. Jahandar Saifollahi, Marjaneh Rouhani, Andrew J. Roth, and Jimmie C. ... Copiously supplemented with over 2500 literature references-1000 more than the first edition-Chronic Lymphoid Leukemias, Second ...
International study suggests improved treatment alternative for lymphoid leukemia Public release date: 11-Feb-2013 CINCINNATI ... When the researchers removed Gfi1 in established mouse lymphoid tumors, the leukemia regressed through p53-induced cell death. ... CINCINNATI - Discovering what they call the Achilles heel for lymphoid leukemia, an international research team has tested a ... International study suggests improved treatment alternative for lymphoid leukemia. Public release date: 11-Feb-2013 ...
... such as the lymphoid transcription factor gene IKZF1 alterations, which are associated with a high rate of leukemic relapse in ... New genetic markers for adult acute lymphoblastic leukemia (ALL) have been found to have prognostic impact, ... of BCR-ABL1+ lymphoid leukemia, including de novo ALL and chronic myeloid leukemia at progression to lymphoid blast crisis, [10 ... 15% of pediatric B-ALL cases; 70% of BCR-ABL1 + lymphoid leukemia, and 30% of high-risk BCR-ABL1-like B-ALL IKZF1 alterations ...
Business Health care industry Blood diseases Diagnosis Hematologic diseases Leukemia ... The chronic leukemias of lymphoid origin, part 1. by Medical Laboratory Observer; ... Chronic leukemias Chronic leukemias of lymphoid origin Chronic lymphocytic leukemia Malignant lymphoma, leukemic phase Hairy ... Chronic leukemias of myeloid origin Chronic myelogenous leukemia Chronic myelomonocytic leukemia Mast cell leukemia Chronic ...
There are mainly 2 types of lymphoid leukemia - acute lymphoid leukemia and chronic lymphoid leukemia. By chronic we mean the ... Lymphoid Leukemia Description - Lymphoid leukemia results from an overabundance of neoplastic white blood cells (lymphocytes) ... This applies for lymphoid leukemia as well. Apart from this it is also important to have adequate information about the subset ... Chronic lymphoid leukemia impairs the bone marrow and results in the under production of other blood cells that are required ...
It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia ( ... antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia ... Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: ... Chimeric antigen receptor-modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in ...
Observations on the effect of a folic-acid antagonist on transplantable lymphoid leukemias in mice.. LAW LW, DUNN TB, et al. ...
Compare myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10 Biomolecules from leading suppliers on Biocompare. View ... Your search returned 8 myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10 Biomolecules across 5 suppliers. ... Transient overexpression lysate of myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to ... myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10 Biomolecules. myeloid/lymphoid or mixed-lineage leukemia; ...
"Myeloid-Lymphoid Leukemia Protein" by people in Harvard Catalyst Profiles by year, and whether "Myeloid-Lymphoid Leukemia ... The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to ... "Myeloid-Lymphoid Leukemia Protein" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH ... Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during ...
CLL is the most common from of adult leukemia in the United States, with about 15,000 new cases and 4,500 deaths annually. An ... Funding from the Leukemia and Lymphoma Society, The D. Warren Brown Foundation, and Calistoga Pharmaceuticals supported this ... study shows that the small-molecule inhibitor CAL-101 directly promotes cell death by apoptosis in chronic lymphocytic leukemia ...
Chromosome specimens of the lymphoid tumor-derived cell lines and normal cat lymphocytes wer ... This study was conducted to map the acquired proviral insertions in the chromosomal genome of feline lymphoid tumors induced by ... Leukemia Virus, Feline / genetics*. Lymphoma / virology*. Mutagenesis, Insertional. Proviruses / genetics*. Virus Integration* ... to map the acquired proviral insertions in the chromosomal genome of feline lymphoid tumors induced by feline leukemia virus ( ...
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy ... Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.. Byrd JC, Brown JR, OBrien S, Barrientos JC, Kay ... BACKGROUND: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response ... Acute Lymphoblastic Leukemia Treatment Acute Myeloid Leukemia Treatment Anal Cancer Treatment Basal Cell Carcinoma Treatment ...
C/ Marc Aureli, número 14 de Barcelona (España) Telf: (93) 217 21 82 Fax: (93) 238 55 00 Correo Electrónico: [email protected] ...
No recapitulation of leukemia was exhibited by any of the conducted culture conditions. Furthermore, the 4-week lymphoid co- ... Lymphoid Progenitor Cells from Childhood Acute Lymphoblastic Leukemia Are Functionally Deficient and Express High Levels of the ... Acute lymphoblastic leukemia (ALL), characterized by the malignant and uncontrolled proliferation of lymphoid precursor cells ... Together, these data suggest that lymphoid progenitor cells from childhood acute lymphoblastic leukemia are functionally ...
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and ... MedlinePlus related topics: Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Leukemia Myelodysplastic Syndromes ... Acute Lymphoblastic Leukemia Myeloid Leukemia Acute Non Lymphoblastic Leukemia ... Patients with B-ALL (B acute lymphoid leukemia) in second or subsequent relapse: should have completed previously ≥1 cycle of a ...
Lymphoid Progenitor Cells from Childhood Acute Lymphoblastic Leukemia Are Functionally Deficient and Express High Levels of the ... "Early lymphoid development and microenvironmental cues in B-cell acute lymphoblastic leukemia," Archives of Medical Research, ... cell subpopulations from patients with chronic myeloid leukemia," Leukemia Research, vol. 28, no. 6, pp. 639-647, 2004. View at ... "In vitro functional alterations in the hematopoietic system of adult patients with acute lymphoblastic leukemia," Leukemia ...
Genetic Relatedness of Lymphoid Malignancies: Transformation of Chronic Lymphocytic Leukemia as a Model Kenneth A. Foon, MD; ... Genetic Relatedness of Lymphoid Malignancies: Transformation of Chronic Lymphocytic Leukemia as a Model. Ann Intern Med. 1993; ... Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine Annals of Internal Medicine; 129 (7): 559-566 ... In the case of large B-cell lymphoma, generally thought to arise from the chronic lymphocytic leukemia clone, approximately one ...
... myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 7), Authors: Olivier Bernard. ... myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 7. ... myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 7. ... FOXO4 (myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 7). Written. 1998-04. ...
Compare and order Myeloid/lymphoid Or Mixed-Lineage Leukemia 2 ELISA Kits. View citations, images, detection ranges, ... myeloid/lymphoid or mixed-lineage leukemia 2 , myeloid/lymphoid or mixed-lineage leukemia protein 2 , LOW QUALITY PROTEIN: ... myeloid/lymphoid or mixed-lineage leukemia 4 , myeloid/lymphoid or mixed-lineage leukemia protein 4 , trithorax homolog 2 , ... mixed lineage leukemia gene homolog 2 , myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 4 , ...
Clinico-hematological profile of patients with B-chronic lymphoid leukemia in Pakistan. - Rozina Zeeshan, Sadia Sultan, Syed ... Clinico-hematological profile of patients with B-chronic lymphoid leukemia in Pakistan.. Abstract. BACKGROUND: Chronic lymphoid ... leukemia (CLL) is not an uncommon hematological malignancy which primarily affects elderly individuals. It is more common in ...
Lymphoid leukemia. 2016 2017 2018 2019 Non-Billable/Non-Specific Code *C91 should not be used for reimbursement purposes as ... personal history of leukemia (. ICD-10-CM Diagnosis Code Z85.6. Personal history of leukemia. 2016 2017 2018 2019 Billable/ ... Leukemia associated with hyperplasia and overactivity of the lymphoid tissue; there are increased numbers of circulating ... Leukemia associated with hyperplasia of the lymphoid tissues and increased numbers of circulating malignant lymphocytes and ...
... to treat dogs diagnosed with lymphoid leukemia or multiple myeloma. ... Canine Lymphoid Leukemia or Multiple Myeloma. Study Name:. Protocol for the Use of TANOVEA-CA1™ (Rabacfosadine for Injection) ... To evaluate efficacy of rabacfosadine to treat dogs with lymphoid leukemia or multiple myeloma ... Use of TANOVEA-CA1™ in Dogs with Lymphoid Leukemia or Multiple Myeloma. ...
CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis ... CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis ... CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis ... Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210(5):917- ...
Acute Lymphoid Leukemia Bone Marrow plasma is obtained by centrifugation of the Acute Lymphoid Leukemia-bone marrow. This ... Acute Lymphoid Leukemia plasma are available in the newly diagnosed and relapsed/refractory stages. ...
Background: Acute lymphoblastic leukemia (ALL) or acute lymphoid leukemia is an acute form of leukemia. Although the mechanism ... Abstract 1297: Increases in the numbers of myeloid-derived suppressor cells in Egyptian children with acute lymphoid leukemia. ... Abstract 1297: Increases in the numbers of myeloid-derived suppressor cells in Egyptian children with acute lymphoid leukemia ... Increases in the numbers of myeloid-derived suppressor cells in Egyptian children with acute lymphoid leukemia. [abstract]. In ...
We studied the combined cytotoxicity of LCPTE against 4 drugs commonly used in the treatment of lymphoid leukemias, vincristine ... Upon further testing of other leukemia cell lines, we unexpectedly found that some lymphoblastic leukemia cell lines were ... We obtained additional lymphoid leukemia cell lines and confirmed that native thiaminase I and linear chain PEGylated ... recombinant thiaminase I enzyme against 4 lymphoid leukemia cell lines. The cells were plated in triplicate wells, incubated in ...
  • Statistical analyses revealed that the combination of venetoclax, a B-cell lymphoma 2 (BCL2) inhibitor, and ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, showed greater clinical benefit compared with either single agent in both myeloid and lymphoid malignancies, including AML, ALL, and CLL. (ahdbonline.com)
  • In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignancies, focusing on chronic neutrophilic leukemia. (ascopost.com)
  • The crosstalk between lymphoid tumor cells and their microenvironment provides pivotal signals for the localization and progression of lymphoid malignancies. (bloodjournal.org)
  • Assess the safety, tolerability and efficacy of rapamycin in combination with HiVAC in relapsed and refractory patients with aggressive lymphoid malignancies. (clinicaltrials.gov)
  • Other Malignancies in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. (mjhid.org)
  • We demonstrate that CRLF2 is overexpressed in approximately 15% of adult and high-risk pediatric B-ALL that lack MLL, TCF3, TEL, and BCR/ABL rearrangements, but not in B-ALL with these rearrangements or other lymphoid malignancies. (pnas.org)
  • The role of Notch has been studied in a wide variety of hematological malignancies including T and B leukemias and lymphomas as well as myeloid leukemias ( 3 - 5 ). (frontiersin.org)
  • 2Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China Abstract: B-cell lymphoma-2 (BCL-2) family dysfunction and impairment of apoptosis are common in most B-cell lymphoid malignancies. (doaj.org)
  • It has also been in clinical trials for other B-cell lymphoid malignancies. (doaj.org)
  • In this review, we describe the role of the BCL-2 family in the pathogenesis of B-cell lymphoid malignancies, the development of venetoclax, and its current clinical outcome in CLL and other B-cell malignancies. (doaj.org)
  • ISLN differs from MCL in that its B-cells are found mainly in lymphoid tissue, it involves different monoclonal B-cell types, and it usually progresses to a set of different types of lymphoid malignancies. (wikipedia.org)
  • With the approval of immune checkpoint-blocking antibodies for Hodgkin lymphoma and bispecific antibodies for acute lymphoblastic leukemia (ALL), activation of endogenous T cells already plays a role in several lymphoid malignancies. (springer.com)
  • Since its inception in 1956, the Lymphoid Malignancies Branch (formerly the Metabolism Branch) has been an exemplar of translational research. (cancer.gov)
  • Primary interests of the Branch concern the identification of abnormalities to the regulation of the immune response and the definition of molecular disorders that underlie lymphoid malignancies. (cancer.gov)
  • the Staudt Laboratory uses genomic approaches to establish a molecular diagnosis of lymphoid malignancies and to discover new targets for therapy of these diseases. (cancer.gov)
  • A recurrent theme that emerges from these unbiased genetic approaches is that lymphoid malignancies co-opt signaling proteins and transcription factors that are used in normal B-cell differentiation and activation. (cancer.gov)
  • IL-2R alpha and IL-2/IL-15R beta) and their signaling pathways through the use of IL-15 in immunotherapy and monoclonal antibodies to receptors (anti-IL-2R alpha and anti-IL-2/IL-15R beta) in the treatment of autoimmune diseases and lymphoid malignancies. (cancer.gov)
  • Our group also focuses on T-cell malignancies with special emphasis on human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T-cell leukemia (ATL) (Kevin Conlon, Thomas Waldmann). (cancer.gov)
  • A major goal of the Branch is to translate fundamental biologic insights into novel treatment of human B and T-cell lymphoid malignancies. (cancer.gov)
  • The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name (for example, adult T-cell leukemia/lymphoma ). (wikipedia.org)
  • In practice, it can be hard to distinguish T-cell leukemia from T-cell lymphoma , and they are often grouped together. (wikipedia.org)
  • Other types include: Large granular lymphocytic leukemia Adult T-cell leukemia/lymphoma T-cell prolymphocytic leukemia In practice, it can be hard to distinguish T-cell leukemia from T-cell lymphoma, and they are often grouped together. (wikipedia.org)
  • A cancer that affects blood cells and the immune system, ALL is the most common type of leukemia in children from infancy up to age 19, according to the Leukemia and Lymphoma Society of America. (fiercebiotech.com)
  • Funding from the Leukemia and Lymphoma Society, The D. Warren Brown Foundation, and Calistoga Pharmaceuticals supported this research. (healthcanal.com)
  • In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. (osu.edu)
  • Clonal diversity of Ig and T-cell receptor gene rearrangements in childhood B-precursor acute lymphoblastic leukaemia," Leukemia and Lymphoma , vol. 36, no. 3-4, pp. 213-224, 2000. (hindawi.com)
  • These B-cell cancers include large B-cell lymphoma (the Richter syndrome), prolymphocytic transformation, acute lymphoblastic leukemia, and multiple myeloma. (annals.org)
  • In the case of large B-cell lymphoma, generally thought to arise from the chronic lymphocytic leukemia clone, approximately one half of the patients had genetically unrelated cancers. (annals.org)
  • Natural killer (NK)/T-cell lymphoid malignancy comprises extra-nodal NK/T-cell lymphoma (ENKTL) and aggressive NK-cell leukemia (ANKL), and the outcomes for advanced or relapsed/refractory ENKTL and ANKL remain poor. (readbyqxmd.com)
  • Leukemia and Lymphoma , 55 (8), 1952-1954. (elsevier.com)
  • Human T-cell leukemia virus I (HTLV-I), endemic in Japan and the Caribbean, is the etiological agent for adult T-cell leukemia/lymphoma, an aggressive adult T-cell leukemia (see Chap. 196 ) . (mhmedical.com)
  • Conjunctival marginal zone lymphoma, mucosa-associated lymphoid tissue-type, with plasmacytic differentiation and MYD88 L265P mutation. (medscape.com)
  • A variant of t(14;18)-negative nodal diffuse follicular lymphoma (FL) with 1p36 deletion has been proposed in the 2017 World Health Organization (WHO) classification of lymphoid neoplasms. (medscape.com)
  • Lymphoid tumors range from low-grade lymphoid hyperplasias to highly malignant lymphoma. (entokey.com)
  • Less common orbital lymphoid lesions like Burkitt lymphoma, T-cell lymphoma, plasmacytoma, and leukemias are also discussed. (entokey.com)
  • Non-Hodgkin lymphoma in the orbit and ocular adnexa can be divided into benign (benign reactive lymphoid hyperplasia [BRLH]), intermediate, or malignant categories. (entokey.com)
  • Lymphoma cell survival and progression are putatively dependent on a specific microanatomic localization within secondary lymphoid organs. (bloodjournal.org)
  • 3 , 4 Although the role of genetic lesions as steps toward cell autonomy and tumor growth has been appreciated, 5 , 6 in vivo the conditions for lymphoma cell lodging within secondary lymphoid organs (SLOs) remain to be addressed. (bloodjournal.org)
  • There is no consensus on the optimal systemic treatment of patients with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. (medpagetoday.com)
  • Zucca E, et al "Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy" J Clin Oncol 2017;35 (17):1905-1912. (medpagetoday.com)
  • The primary objective of this study is to determine the maximum tolerated dose, dose-limiting toxicities, safe starting dose, and pharmacodynamic effect of TANOVEA™ (Rabacfosadine for injection) in cats with lymphoma, lymphoid leukemia or multiple myeloma/plasma cell tumor. (vcchope.com)
  • 2-Aisenberg AC, Wilkes BM, Jacobson J. Rearrangement of the Genes for the Beta and Gamma Chains of the T Cell Receptor Is Rarely Observed in Adult B Cell Lymphoma and Chronic Lymphocytic Leukemia. (mjhid.org)
  • Peripheral T-cell Lymphomas With Cytotoxic Phenotype in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (mjhid.org)
  • HCL must be distinguished from other indolent lymphoid neoplasias such as prolymphocytic leukemia, splenic marginal zone lymphoma, the variant of HCL (HCLv), and mantle cell lymphoma. (uanl.mx)
  • In situ lymphoid neoplasia (ISLN, also termed in situ lymphoma) is a precancerous condition newly classified by the World Health Organization in 2016. (wikipedia.org)
  • Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is the third most common non-Hodgkin lymphoma subtype, accounting for around 6-8% of all non-Hodgkin lymphomas in the Western hemisphere. (bmj.com)
  • To retrospectively analyze the clinical course of patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma of the parotid gland and associated Sjögren's syndrome (SS). (jrheum.org)
  • Four percent to 7% 1 , 2 of patients with SS develop malignant B cell lymphoma, 48%-75% of which are of the mucosa-associated lymphoid tissue (MALT)-type. (jrheum.org)
  • The chronic leukemias, which are the focus of this discussion, are genetically identical or clonal proliferations of myeloid or lymphoid cells which, in contrast to acute leukemias, are characterized by the accumulation of relatively more mature cells within the blood, bone marrow, and parenchymal organs. (thefreelibrary.com)
  • Chronic lymphoid leukemia impairs the bone marrow and results in the under production of other blood cells that are required for combating inflammations, allergies and infections. (wearethecure.org)
  • In acute lymphoid leukemia, the bone marrow is obliterated by the over abundance of lymphoblasts (immature cells that differentiate to form mature lymphocytes). (wearethecure.org)
  • Acute lymphoblastic leukemia - Aggressive therapy is needed is restore hemastopoiesis (growth of blood cells) because acute lymphoblastic leukemia causes complete compression of the bone marrow. (wearethecure.org)
  • Substantial progress on understanding the cell hierarchy within ALL bone marrow (BM) has been recorded in the last few years, suggesting that both primitive cell fractions and committed lymphoid blasts with immature stem cell-like properties contain leukemia-initiating cells. (hindawi.com)
  • Acute lymphoblastic leukemia (ALL), characterized by the malignant and uncontrolled proliferation of lymphoid precursor cells within bone marrow (BM), is the hematological disorder with the highest frequency in childhood and the most common cause of mortality in children worldwide [ 1 - 5 ]. (hindawi.com)
  • Acute Lymphoid Leukemia Bone Marrow plasma is obtained by centrifugation of the Acute Lymphoid Leukemia-bone marrow. (creative-bioarray.com)
  • Bone Marrow is obtained from adult Acute Lymphoid Leukemia patients. (creative-bioarray.com)
  • Acute Lymphoid Leukemia (ALL), also known as acute lymphoblastic leukemia, is a disease of the lymphoid cells found in the bone marrow. (chemoexperts.com)
  • In acute lymphoblastic leukemia (ALL), the malignant clone arises from hematopoietic progenitors in the bone marrow or lymphatic system resulting in an increase of immature nonfunctioning leukemic cells. (mhmedical.com)
  • The diagnosis of acute leukemia is made by examination of the peripheral blood and bone marrow. (mhmedical.com)
  • By definition, leukemia is a malignancy in the cells that make our blood, which are located in the bone marrow - that spongy material in the center of our bones. (cancerhorizons.com)
  • Myeloid tissues are most known as the blood forming cells in our bone marrow, while lymphoid tissue in the bone marrow is less organized and is related to the immune system. (cancerhorizons.com)
  • The other systems studied were injection of the IFN-γ inducer polyinosinic:polycytidylic acid, infection by the BM5 variants of murine leukemia virus (the causative agent of murine AIDS), and T cell expansion after transfer of normal bone marrow and lymph node cells into recombinase-activating gene-2-deficient mice. (jimmunol.org)
  • Leukemic cells originate from the malignant transformation of undifferentiated myeloid/lymphoid hematopoietic progenitors normally residing in bone marrow. (elsevier.com)
  • This is a long shot but, my grandpa has a rare form of leukemia and is in need of a stem cell/bone marrow donor. (wn.com)
  • Leukemia subgroups included acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia, and myeloproliferative neoplasms/myelodysplastic syndrome. (ahdbonline.com)
  • In this review, we summarize the mechanisms of action and clinical data on trials in the lymphoid neoplasms with chimeric antigen receptor T cells, bispecific antibodies, immune checkpoint-blocking antibodies, and antineoplastic vaccination therapy. (springer.com)
  • 202 ...................................... Other malignant neoplasms of lymphoid and histiocytic tissue. (cdc.gov)
  • Ag-driven BCR selection via affinity maturation is believed to take place primarily in germinal centers (GCs) in secondary lymphoid organs where the processes of class switch recombination (CSR) and somatic hypermutation (SHM) of the Ig genes takes place in GC B cells ( 4 ). (jimmunol.org)
  • However, CSR and low-level SHM have also been shown to occur at extrafollicular sites in rodent secondary lymphoid organs ( 5 ). (jimmunol.org)
  • Tfh cells regulate the differentiation and survival of activated B cells outside and inside germinal centers (GC) of secondary lymphoid organs. (plos.org)
  • Here we show that neuropilin 1 (Nrp1), a cell surface receptor, is selectively expressed by a subset of Tfh cells in human secondary lymphoid organs. (plos.org)
  • In mouse and human secondary lymphoid organs, Tfh cells are characterized by the expression of CXCR5, the costimulatory molecules ICOS, PD-1 and OX40, and the transcriptional repressor Bcl-6 [ 1 - 3 ]. (plos.org)
  • Tfh cells interact with B cells in secondary lymphoid organs, but there is currently no specific T cell marker for this activity. (plos.org)
  • Leukemia associated with hyperplasia of the lymphoid tissues and increased numbers of circulating malignant lymphocytes and lymphoblasts. (icd10data.com)
  • Acute lymphoblastic leukemia (ALL) is a malignant disease of lymphoid progenitor cells. (readbyqxmd.com)
  • T cell acute lymphoblastic leukemias (T-ALLs) arise from the malignant transformation of hematopoietic progenitors primed toward T cell development, as result of a multistep oncogenic process involving constitutive activation of NOTCH signaling and genetic alterations in transcription factors, signaling oncogenes, and tumor suppressors. (jci.org)
  • T cell acute lymphoblastic leukemias (T-ALLs) are aggressive hematologic tumors resulting from the malignant transformation of T cell progenitors. (jci.org)
  • Williams Hematology Malignant Lymphoid Diseases Press OW, Lichtman MA, Leonard JP. (mhmedical.com)
  • CLL is a malignant lymphoid neoplasm that is characterized by the accumulation of a population of small mature B cells. (mhmedical.com)
  • Chronic autoimmune or pathogen-induced immune reactions resulting in lymphoid neogenesis are associated with development of malignant lymphomas, mostly extranodal marginal zone B-cell lymphomas (MZBCLs). (haematologica.org)
  • Recently, however, monoclonal B-cells with some key characteristics of the malignant B-cells in FL or MCL have been found to accumulate in one or more lymphoid tissues. (wikipedia.org)
  • [1] It causes 15% of acute leukemias in childhood, and also 40% of lymphomas in childhood. (wikipedia.org)
  • Additionally, MYD88 L265P may be found in chronic lymphocytic leukemia (CLL), SMZL, and other B-cell lymphomas, where it may be associated with specific clinical and diagnostic features. (medscape.com)
  • The low-grade mucosa-associated lymphoid tissue (MALT) lymphomas, which can also occur in the orbit, are discussed in the conjunctival section. (entokey.com)
  • CHRONIC LYMPHOID LEUKEMIAS/LYMPHOMAS is a topic covered in the Harrison's Manual of Medicine . (unboundmedicine.com)
  • harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623596/all/CHRONIC_LYMPHOID_LEUKEMIAS_LYMPHOMAS. (unboundmedicine.com)
  • In this review, we will summarize the evidence for oncogenic and tumor suppressor roles of Notch in a wide range of leukemias and lymphomas, and describe therapeutic opportunities for now and the future. (frontiersin.org)
  • In this review, we will outline the roles of the Notch pathway in a wide variety of leukemias and lymphomas, describe potential targeted therapies and discuss future directions. (frontiersin.org)
  • Lymphoid leukemias are a group of leukemias affecting circulating lymphocytes , a type of white blood cells . (wikipedia.org)
  • Most lymphoid leukemias involve a particular subtype of lymphocytes, the B cells . (wikipedia.org)
  • Description - Lymphoid leukemia results from an overabundance of neoplastic white blood cells (lymphocytes) into the peripheral blood. (wearethecure.org)
  • Although elevation of lymphocytes is the most important indicator for lymphoid leukemia, the low number of white blood cells in the initial stages makes the diagnostic process extremely difficult. (wearethecure.org)
  • In B-cell chronic lymphoid leukemia where the lymphocytes play a key role in the humoral immune response (immunity that is mediated by secreted antibodies produced in B-cells), the marrow is invaded with mature lymphocytes. (wearethecure.org)
  • Apart from this it is also important to have adequate information about the subset of lymphocytes in healthy dogs because the expansion of this same would be a marker for lymphoid leukemia in dogs. (wearethecure.org)
  • Chromosome specimens of the lymphoid tumor-derived cell lines and normal cat lymphocytes were subjected to fluorescence in situ hybridization and tyramide signal amplification, using an exogenous FeLV-A genome as a probe. (biomedsearch.com)
  • In normal animals, very small numbers of cycling mature lymphocytes are detected in peripheral lymphoid organs ( 9 , 10 ). (jimmunol.org)
  • Because B chronic lymphoid leukemia (B-CLL) cells exhibit a defective apoptotic response, we analyzed CD19(+) B lymphocytes purified from the peripheral blood of B-CLL patients. (units.it)
  • B) the interplay between CXCL13-producing stromal cells and increasing numbers of mLTα1β2 and TNF-expressing B lymphocytes, leads to the development of follicular dendritic cells (FDCs) and subsequent formation of lymphoid follicles. (haematologica.org)
  • ISFN and ISMCL are pathological accumulations of lymphocytes in the germinal centers and mantle zones, respectively, of the follicles that populate lymphoid organs such as lymph nodes. (wikipedia.org)
  • Lymphoid stem cells develop into lymphoblasts which develop into lymphocytes. (cancer.ca)
  • The primary lesion is the transformation of B lymphocytes in the lymphoid follicles of the bursa of Fabricius, but multiple metastatic lesions occur in the liver, spleen, etc. (thefreedictionary.com)
  • A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. (lookfordiagnosis.com)
  • DNA synthesis was preceded by massive migration of Vβ8 + cells from blood to lymphoid organs, in which the early activation marker CD69 was first up-regulated. (jimmunol.org)
  • small foci of lymphoid tissue which occur in almost all parenchymatous organs in birds. (thefreedictionary.com)
  • Acute lymphoblastic leukemia (ALL) is a biologically and clinically heterogeneous neoplasm of lymphoid progenitors, with approximately 85% of cases being of B-cell lineage and 15% of T-cell lineage. (biomedsearch.com)
  • Nevertheless, the biology of the early progenitors that initiate the lymphoid program remains elusive. (hindawi.com)
  • The aim of the present study was to investigate the ability of lymphoid progenitors from B-cell precursor ALL BM to proliferate and undergo multilineage differentiation. (hindawi.com)
  • Moreover, neither B nor NK or dendritic lymphoid-cell populations developed recurrently from highly purified ALL-lymphoid progenitors, and their proliferation and cell cycle status revealed limited proliferative capacity. (hindawi.com)
  • Interferon-producing killer dendritic cells (IKDCs) arise via a unique differentiation pathway from primitive c-kitHiCD62L + lymphoid progenitors," Blood , vol. 109, no. 11, pp. 4825-4831, 2007. (hindawi.com)
  • These observations clearly indicate that T lymphoid and myeloid blasts share common Ph 1 -positive progenitors, and that Phi-positive T lymphoid/myeloid progenitors are probably involved in the development of blastic transformation in some percentage of CML patients. (elsevier.com)
  • When the researchers removed Gfi1 in established mouse lymphoid tumors, the leukemia regressed through p53-induced cell death. (fiercebiotech.com)
  • This study was conducted to map the acquired proviral insertions in the chromosomal genome of feline lymphoid tumors induced by feline leukemia virus (FeLV). (biomedsearch.com)
  • The classification of lymphoid tumors is complex, discussed in textbooks and articles, and beyond the scope of this textbook. (entokey.com)
  • Lymphoid tumors that arise in the lacrimal gland should be differentiated from primary epithelial tumors of the lacrimal gland. (entokey.com)
  • Lymphoid tumors generally have an oblong, ovoid, or pancake contour and mold to the globe and orbital bones, usually without producing a bony fossa or bony erosion. (entokey.com)
  • As mentioned, many orbital/adnexal lymphoid tumors are derived from MALT ( 20 , 26 ). (entokey.com)
  • B-cell leukemia describes several different types of lymphoid leukemia which affect B cells . (wikipedia.org)
  • Aggressive NK-cell leukemia (ANKL) is a lymphoid leukemia that is a deficiency NK cells. (wikipedia.org)
  • [9] One problem when using NK cells in order to fight off lymphoid leukemia is the fact that it is hard to amount enough of them to be effective. (wikipedia.org)
  • To this end, lymphoid leukemias can also be divided by the type of cells affected: B-cell leukemia T-cell leukemia NK-cell leukemia The most common type of lymphoid leukemia is B-cell chronic lymphocytic leukemia. (wikipedia.org)
  • Other types include (with ICD-O code): 9826/3 - Acute lymphoblastic leukemia, mature B-cell type 9833/3 - B-cell prolymphocytic leukemia 9940/3 - Hairy cell leukemia T-cell leukemia describes several different types of lymphoid leukemias which affect T cells. (wikipedia.org)
  • The requirements for diagnosing ANKL are as follows: Immature-looking NK cells Certain immunophenotypes Germline configuration genes: TCR-β and IgH Restricted cytotoxicity The T-cell receptor (TCR) is an important factor when ANKL is being diagnosed along with T-cell leukemia. (wikipedia.org)
  • Removing the protein in mouse models of the disease weakened and killed the leukemia cells. (fiercebiotech.com)
  • Gfi1 has an important role in the normal development of lymphoid cells. (fiercebiotech.com)
  • Next, to see if removal of Gfi1 would be effective in modeled human ALL, the research team inserted T-cell leukemia cells from human patients into mice. (fiercebiotech.com)
  • The chronic leukemias are clonal disorders and typically present as a proliferation of mature lymphold cells. (thefreelibrary.com)
  • Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). (nih.gov)
  • It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL). (nih.gov)
  • Chimeric antigen receptor-modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. (nih.gov)
  • H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. (harvard.edu)
  • Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. (harvard.edu)
  • Their study shows that the small-molecule inhibitor CAL-101 directly promotes cell death by apoptosis in chronic lymphocytic leukemia (CLL) cells and disrupts several external survival pathways needed for CLL cell viability and proliferation. (healthcanal.com)
  • Molecular cytogenetic analysis of feline leukemia virus insertions in cat lymphoid tumor cells. (biomedsearch.com)
  • Moreover, the understanding of the mechanisms that damage the earliest steps of the lymphoid developmental program in ALL is incomplete, and the existence of specialized cancer stem cells is still a debate [ 8 ]. (hindawi.com)
  • Furthermore, data showing that only cells with immature phenotypes are capable of engraftment and leukemia reconstitution in immunodeficient mice models support this [ 9 - 12 ]. (hindawi.com)
  • Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection," Blood , vol. 112, no. 9, pp. 3753-3761, 2008. (hindawi.com)
  • A progressive, proliferative disease of blood cells, originating from lymphoid cells. (icd10data.com)
  • Innate lymphoid cells (ILCs), defined as lineage negative (Lin − ) CD127 + cells, have emerged as novel important immune effector cells, playing a critical role also in tumor immunosurveillance. (haematologica.org)
  • ILCs are a novel family of lineage negative CD127 + innate immune cells belonging to the lymphoid lineage, yet not expressing rearranged antigen specific receptors. (haematologica.org)
  • In addition, the IC 50 of 3 of the 5 leukemia cell lines (Reh, RS4, and Jurkat) were at least 1,000-fold more sensitive than Molt-4 cells, which in turn, were among the most sensitive in the NCI60 panel. (aacrjournals.org)
  • The proliferation of chronic lymphocytic leukemia (CLL) cells requires communication with the lymphoid organ microenvironment. (aacrjournals.org)
  • Furthermore, we established a mouse model of CLL in which B cell-specific genetic ablation of ILK resulted in decelerated leukemia development due to reduced organ infiltration and proliferation of CLL cells. (aacrjournals.org)
  • These results suggest that the P120 product of the A-MuLV genome may be responsible for maintenance of the transformed phenotype of lymphoid and fibroblast cells transformed by the virus. (caltech.edu)
  • Purpose: Classification of acute leukemia (AL) is based on commitment of leukemic cells to the myeloid or the lymphoid lineage. (aacrjournals.org)
  • The anti-neoplastic activity of ethylamine-carboxyborane and triphenylphosphine-carboxyborane in L-1210 lymphoid leukemia cells. (docme.ru)
  • These important preclinical findings demonstrated that both lymphoid- and acute myeloid-derived primary leukemia cells show sensitivity to combined inhibition of BCL2 and BTK with the combination of venetoclax and ibrutinib, suggesting this combination may have broad therapeutic indications. (ahdbonline.com)
  • Detection of myeloperoxidase activity in primary leukemic cells by an enhanced chemiluminescent assay for differentiation between acute lymphoblastic and non-lymphoblastic leukemia. (semanticscholar.org)
  • Lymphoid cells are responsible for developing into cells of the immune system called B-cells, T-cells, or Natural Killer cells. (chemoexperts.com)
  • In ALL, immature lymphoid cells know as "blasts" replicate at a very fast rate. (chemoexperts.com)
  • Their mixed B-lymphoid/myeloid characteristics strongly suggest that so-called 'Ph+ AML' is derived from Ph+ myeloid/B-lymphoid stem cells. (elsevier.com)
  • Chronic lymphocytic leukemia (CLL) cells survive and thrive not just by their own innate wiles, but by also acquiring aid and support from host cells in their surrounding environment. (scienceblog.com)
  • Chronic lymphocytic leukemia is a malignancy of mature B cells characterized by progressive lymphocytosis, lymphadenopathy, splenomegaly, and cytopenias. (mhmedical.com)
  • The diagnosis of CLL requires the presence of at least 5000 circulating B cells/ μ L, with clonality demonstrated by flow cytometry according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria. (mhmedical.com)
  • Here we demonstrate a unique function for the transcription factor lymphoid enhancer factor 1 (LEF1) in the postselection expansion of iNKT cells through a direct induction of the CD127 component of the receptor for interleukin-7 (IL-7) and the transcription factor c- myc . (rupress.org)
  • However, 1) MBL disorders can progress to FL or MCL, 2) small numbers of the B-cells involved in ISFN may circulate in individuals who have or will develop ISFN, and 3) the B-cells in MBL may accumulate in lymphoid tissues. (wikipedia.org)
  • The disorder involves an accumulation of monoclonal B-cells in the germinal centers of lymphoid tissue. (wikipedia.org)
  • 2017) Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. (springer.com)
  • In the earliest stage of blood cell development, stem cells begin to develop either along the lymphoid cell line or the myeloid cell line. (cancer.ca)
  • For a long time, natural killer (NK) cells were thought to be the only innate immune lymphoid population capable of responding to invading pathogens under the influence of changing environmental cues. (frontiersin.org)
  • In the last few years, it has become evident that the innate immune system displays a similar strategy in order to ensure a first line of defense against intruders via innate lymphoid cells (ILCs). (frontiersin.org)
  • Innate lymphoid cells, like Th cells, are heterogeneous and currently grouped in three major subsets: ILC1, ILC2, and ILC3 ( 5 ). (frontiersin.org)
  • Innate lymphoid cells (ILCs) are emerging as important regulators of homeostatic and disease-associated immune processes. (rupress.org)
  • Innate lymphoid cells (ILCs) reside primarily at barrier surfaces where they play key roles in maintaining mucosal homeostasis and protecting against infection. (rupress.org)
  • A B-cell leukemia is any of several types of lymphoid leukemia which affect B cells . (wn.com)
  • children may have small, dark spots that look like common rashes if the leukemia cells spread to the skin. (wn.com)
  • 14- 16 The neoplastic cells infiltrate around reactive secondary lymphoid follicles in a marginal zone distribution and spread outwards to form diffuse interfollicular sheets or, in some cases, a vaguely nodular pattern. (bmj.com)
  • Typically, they are diagnosed based on the findings in lymphoid tissues examined for other reasons. (wikipedia.org)
  • ISFL and ISMCL are generally asymptomatic disorders discovered in lymphoid tissues which were examined for other reasons. (wikipedia.org)
  • In addition, no information is available on whether CSR and SHM can take place in the absence of GCs at extrafollicular sites in an ectopic lymphoid tissue. (jimmunol.org)
  • Chronic inflammatory conditions, due to improper eradication of pathogens, auto-immune processes or chronic allograft rejections, are associated with the genesis of organized lymphoid tissue. (haematologica.org)
  • In recent years, a number of key molecular determinants operating during the generation of tertiary lymphoid tissue, have been identified. (haematologica.org)
  • lym·phoid/ ( lim´foid ) resembling or pertaining to lymph or tissue of the lymphoid system. (thefreedictionary.com)
  • IRRADIATION TREATMENT OF LYMPHOID HYPERPLASIA OF THE NASOPHARYNX Irradiation is useful in the destruction of hypertrophied lymphoid tissue which cannot be surgically removed.Beta, gamma and roentgen rays have been used for this purpose. (tripdatabase.com)
  • damage considered, choice of method depends upon the location and extent of the excess lymphoid tissue to be destroyed and the mechanical difficulties of reaching it with effective irradiation without hazard to intervening or surrounding tissue. (tripdatabase.com)
  • In this study, we show that p38α regulates gut-associated lymphoid tissue (GALT) formation in a noncell-autonomous manner. (tripdatabase.com)
  • Epithelial control of gut-associated lymphoid tissue formation through p38α-dependent restraint of NF-κB signaling The protein kinase p38α mediates cellular responses to environmental and endogenous cues that direct tissue homeostasis and immune responses. (tripdatabase.com)
  • Greyson Veal began fighting for his life, again, when his b-cell acute Lymphoblastic Leukemia relapsed in December 2020. (wn.com)
  • There are mainly 2 types of lymphoid leukemia - acute lymphoid leukemia and chronic lymphoid leukemia. (wearethecure.org)
  • In contrast with reactive lymphoid hyperplasia, the nuclei are somewhat larger, prominent nucleoli are sometimes present, and abortive follicles may be observed. (entokey.com)
  • Similar problems are encountered in the diagnosis of lymphoproliferative disorders, although certain disorders such as hairy cell leukemia (HCL) can be quite distinctive morphologically. (thefreelibrary.com)
  • Myeloid-Lymphoid Leukemia Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
  • Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. (harvard.edu)
  • The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS. (harvard.edu)
  • This graph shows the total number of publications written about "Myeloid-Lymphoid Leukemia Protein" by people in Harvard Catalyst Profiles by year, and whether "Myeloid-Lymphoid Leukemia Protein" was a major or minor topic of these publication. (harvard.edu)
  • Below are the most recent publications written about "Myeloid-Lymphoid Leukemia Protein" by people in Profiles. (harvard.edu)
  • In vitro and in vivo lymphocyte function was studied in six patients with primary hypogammaglobulinaemia and nodular lymphoid hyperplasia (NLH) of the bowel. (tripdatabase.com)
  • Acute lymphoblastic leukemia (ALL) is the most frequent malignancy of childhood. (hindawi.com)
  • Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. (mjhid.org)
  • Copiously supplemented with over 2500 literature references-1000 more than the first edition-Chronic Lymphoid Leukemias, Second Edition fulfills the reference needs of oncologists, hematologists, immunologists, pathologists, infectious disease specialists, internists, molecular biologists, and medical school students in these disciplines. (routledge.com)
  • Reporting their results Feb. 11 in the journal Cancer Cell, the scientists said the targeted molecular therapy described in their study could have direct implications for current treatment of Acute Lymphoid Leukemia (ALL) in people. (fiercebiotech.com)
  • Extracts from lymphoid and fibroblast cell lines transformed by Abelson murine leukemia virus (A-MuLV) contain a protein of molecular weight 120,000 (P120). (caltech.edu)
  • These results strongly support the notion that ectopic lymphoid structures in SS-SGs express the molecular machinery to support local autoantibody production and B cell expansion and may play a crucial role toward lymphomagenesis. (jimmunol.org)
  • COLUMBUS, Ohio -- A study shows for the first time that the three most common chromosome changes seen in chronic lymphocytic leukemia disrupt a molecular network that includes several important genes and strongly influences the outcome of the disea. (scienceblog.com)
  • HOUSTON - The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers. (scienceblog.com)
  • Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. (openrepository.com)
  • As the precise molecular mechanisms underlying this heterogeneous disease are yet to be disclosed, the identification and the validation of novel actors in leukemia is of extreme importance. (elsevier.com)
  • Collectively, data here presented indicate that KCTD15 is an important and hitherto unidentified player in childhood lymphoid leukemia, and its study could open a new scenario for the identification of altered and still unknown molecular pathways in leukemia. (elsevier.com)
  • Historically, they have been most commonly divided by the stage of maturation at which the clonal (neoplastic) lymphoid population stopped maturing: Acute lymphoblastic leukemia Chronic lymphocytic leukemia However, the influential WHO Classification (published in 2001) emphasized a greater emphasis on cell lineage. (wikipedia.org)
  • Maintenance of neural stem cell positional identity by mixed-lineage leukemia 1. (harvard.edu)
  • E. Dorantes-Acosta and R. Pelayo, "Lineage switching in acute leukemias: a consequence of stem cell plasticity? (hindawi.com)
  • MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia. (aacrjournals.org)
  • These leukemias of ambiguous lineage represent a heterogeneous category of AL that cannot be classified as either myeloid AL (AML) or lymphoid AL (ALL). (aacrjournals.org)
  • The lack of clear classification of acute leukemias of ambiguous lineage as either AML or ALL is a hurdle in treatment choice for these patients. (aacrjournals.org)
  • Experimental design: here, we compared the microRNA expression profiles of 17 cases with AL of ambiguous lineage and 16 cases of AML, B-ALL and T-ALL Results: We show that leukemias of ambiguous lineage do not segregate as a separate entity but exhibit microRNA expression profiles similar to either AML, B-ALL or T-ALL. (aacrjournals.org)
  • Conclusions: Our results indicate the presence of a myeloid or lymphoid lineage specific genotype, as reflected by microRNA expression, in these AL despite their ambiguous immunophenotype. (aacrjournals.org)
  • Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma. (semanticscholar.org)
  • By using an adaptor-ligation/suppression-PCR, we identified four integrations into the myeloid/lymphoid or mixed-lineage leukemia 4 (MLL4) gene from 10 HCC patients with positive HBV surface antigen (HBsAg). (semanticscholar.org)
  • Unlike other chromosomal translocations, which are usually specific for a given lineage, the chromosomal translocation t(12;13)(p12;q14) has been observed in both B-cell and T-cell precursor acute lymphoblastic leukemia (BCP-, TCP-ALL), in differentiated and undifferentiated acute myeloblastic leukemia (AML), and in chronic myeloid leukemia (CML) at progression to blast crisis. (openrepository.com)
  • Broadly, ILCs are defined by their lymphoid lineage and their lack of RAG-mediated recombined antigen receptors. (frontiersin.org)
  • In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties," Cancer Cell , vol. 14, no. 1, pp. 47-58, 2008. (hindawi.com)
  • A simple and sensitive chemiluminescence assay for the demonstration of the activity of intracellular myeloperoxidase (MPO) is described, which is useful for the distinction between myeloid and lymphoid commitment in blasts from acute leukemia patients. (semanticscholar.org)
  • Dose escalation: To determine the maximum tolerated dose (MTD) of SAR440234 administered as a single agent in patients with R/R AML (relapsed or refractory acute myeloid leukemia), HR-MDS (high risk myelodysplastic syndrome), or B-ALL (B-cell acute lymphoblastic leukemia), and determine the recommended phase 2 dose (RP2D) for the subsequent Expansion part. (clinicaltrials.gov)
  • Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph(+) acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. (nih.gov)
  • In case 2, morphocytochemically distinct myeloid and lymphoid blast populations were seen. (elsevier.com)
  • In both cases, morphocytochemically distinct myeloid and T lymphoid blast populations proliferated simultaneously in the phase of blastic crisis-myeloperoxidase (MPO)-positive, CD7 + /CD33 + myeloblasts in the peripheral blood, and MPO-negative, periodic acid Schiff (PAS)-positive lymphoblasts in the lymph nodes. (elsevier.com)
  • Acute Lymphoid Leukemia plasma are available in the newly diagnosed and relapsed/refractory stages. (creative-bioarray.com)
  • The conclusive diagnosis of any of the chronic leukemias requires a skilled morphologist, but early consideration of these disorders and prompt referral can result not only in more efficient patient management, but also in considerable cost savings to the laboratory and hospital. (thefreelibrary.com)
  • Once a diagnosis of a chronic leukemia is made, the laboratory supervisor, armed with knowledge of the disorders, can help guide decisions on the extent of laboratory testing to ensure that appropriate and cost-effective choices are made. (thefreelibrary.com)
  • A diagnosis of chronic leukemia may be first suspected in an older adult who is found to have an elevated white cell count but who is otherwise in good health. (thefreelibrary.com)
  • Much of the diagnosis of chronic leukemia is based on the morphologic examination of the peripheral blood smear. (thefreelibrary.com)
  • The duration of the diagnosis/treatment phase for the "Chronic lymphoid leukemia" group is based on expert opinion on the average length of treatment that patients undergo after the initial diagnosis of CLL. (healthdata.org)
  • By phenotype analyses, in vitro proliferation assays, and controlled culture systems, the lymphoid differentiation potentials were evaluated in BM primitive populations from B-cell precursor ALL pediatric patients. (hindawi.com)
  • P. Diamanti, C. V. Cox, J. P. Moppett, and A. Blair, "Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia," Blood , vol. 121, pp. 1384-1393, 2013. (hindawi.com)
  • In the last few years, an increasing amount of evidence has shown that a number of different innate lymphoid cell (ILC) populations found at mucosal sites rapidly respond to locally produced cytokines in order to establish or maintain homeostasis. (frontiersin.org)
  • The chronic leukemias of lymphoid origin, part 1. (thefreelibrary.com)
  • Chronic leukemias are a complex group of blood disorders that can be quite insidious in their appearance. (thefreelibrary.com)
  • As their name implies, chronic leukemias have a longer clinical course than their acute counterparts. (thefreelibrary.com)
  • Table 1 illustrates a general classification scheme for the chronic leukemias. (thefreelibrary.com)
  • Part one describes representative examples of the chronic leukemias of lymphoid origin, while part two (to be published in an upcoming issue) will discuss chronic leukemias of myeloid origin. (thefreelibrary.com)
  • This category includes precursor or acute lymphoblastic leukemias and chronic leukemias. (icd10data.com)
  • Natural killer (NK) cell therapy is used in pediatrics for children with relapsed lymphoid leukemia. (wikipedia.org)
  • To date, such specific antigens have not been identified in leukemias. (cqdm.org)
  • Ph+ myeloblasts co-expressed myeloid and B-lymphoid antigens (CD10, CD13, CD19 and CD33). (elsevier.com)
  • Cell Differentiation Antigens versus Tumor-Related Antigens in Childhood Acute Lymphoblastic Leukemia (ALL). (springer.com)
  • The most common T-cell leukemia is precursor T-cell lymphoblastic leukemia . (wikipedia.org)
  • [1] Its morphology is identical to that of precursor B-cell lymphoblastic leukemia . (wikipedia.org)
  • To describe the incidence of acute neurotoxicity (NT) in children with lower risk B-precursor acute lymphoid leukemia (ALL) treated with intermediate-dose methotrexate (MTX) or divided dose oral MTX with or without intravenous (i.v.) mercaptopurine (MP) and extended intrathecal triple therapy. (uni-bonn.de)
  • The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. (pnas.org)
  • Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. (harvard.edu)
  • Clinico-hematological profile of patients with B-chronic lymphoid leukemia in Pakistan. (curehunter.com)
  • 1 - 5 Recently, it was shown that the number of ILCs in acute myeloid leukemia (AML) patients is significantly reduced after chemotherapy/radiotherapy as compared to healthy donors. (haematologica.org)
  • Materials and Methods: Upon informed consent, patients with B-Linage Acute Lymphoblastic Leukemia "B-ALL" (n = 20) were recruited in this study along with healthy volunteers (n = 20). (aacrjournals.org)
  • Specimens isolated from 588 patients with leukemia were evaluated in the presence of a graded-concentration panel of more than 120 single-agent inhibitors or combinations spanning several different drug classes. (ahdbonline.com)
  • A partial tandem duplication within the MLL-gene (MLL-PTD) can be found in 8% of all patients with karyotypically normal acute myeloid leukemia (AML). (biomol.com)
  • Invasive fungal diseases in patients with acute lymphoid leukemia. (readbyqxmd.com)
  • Invasive fungal disease (IFD) represents an important complication in patients with acute lymphoid leukemia (ALL). (readbyqxmd.com)
  • Philadelphia-positive (Ph(+)) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. (nih.gov)
  • There is a twentyfold increased incidence of leukemia in patients with Down syndrome, in whom ALL is increased in childhood or AML at an older age. (mhmedical.com)
  • ROCHESTER, Minn. -- Researchers at Mayo Clinic (http://www.mayoclinic.org/) have found a significant difference in cancer progression and death in chronic lymphocytic leukemia (CLL) patients who had sufficient vitamin D (http://www.mayoclinic.com/he. (scienceblog.com)
  • It was approved for treatment of previously treated chronic lymphocytic leukemia (CLL) patients with 17p deletion early in 2016. (doaj.org)
  • Chromosomal changes detected by fluorescence in situ hybridization in patients with acute lymphoblastic leukemia. (openrepository.com)
  • Here, we show that KCTD15, a member of the emerging class of KCTD ((K)potassium Channel Tetramerization Domain containing) proteins, is strongly upregulated in patients affected by B-cell type acute lymphoblastic leukemia (B-ALL) and in continuous cell lines (RS4;11, REH, TOM-1, SEM) derived from this form of childhood leukemia. (elsevier.com)
  • Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. (nih.gov)
  • Children that have Down Syndrome , also known as Trisomy 21 - an extra copy of the 21st chromosome - stand a 2-3% chance of developing either acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML). (cancerhorizons.com)
  • We report two cases of Philadelphia chromosome (Ph)-positive acute leukemia with definite myeloid markers. (elsevier.com)
  • Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia. (openrepository.com)
  • To begin to define the gene(s) involved on chromosome 13, we have performed fluorescence in situ hybridization (FISH) using a panel of YACs from the region, on a series of 10 cases of acute leukemia with t(12;13)(p12;q14) and 1 case each with "variant" translocations including t(12;13)(q21;q14), t(10;13)(q24;q14) and t(9;13)(p21;q14). (openrepository.com)
  • Analysis of balanced rearrangements of chromosome 6 in acute leukemia: clustered breakpoints in q22-q23 and possible involvement of c-MYB in a new recurrent translocation, t(6;7)(q23;q32 through 36). (openrepository.com)
  • Acute lymphoblastic leukemia, with a PH positive and a Philadelphia chromosome , is what he was told that he had. (wn.com)
  • It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. (lookfordiagnosis.com)
  • New recurring chromosomal translocations in childhood acute lymphoblastic leukemia. (openrepository.com)
  • The most common type of lymphoid leukemia is B-cell chronic lymphocytic leukemia . (wikipedia.org)
  • The T-cell receptor (TCR) is an important factor when ANKL is being diagnosed along with T-cell leukemia . (wikipedia.org)
  • A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia," Blood , vol. 95, no. 3, pp. 1007-1013, 2000. (hindawi.com)
  • Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia," Nature Medicine , vol. 11, no. 6, pp. 630-637, 2005. (hindawi.com)
  • Studies concerning the genetic relatedness between chronic lymphocytic leukemia and the more aggressive B-cell cancers that develop in about 10% of affected persons were reviewed. (annals.org)
  • These data indicate that progression to more aggressive B-cell cancers in persons with chronic lymphocytic leukemia can result from either clonal evolution or from an independent transforming event. (annals.org)
  • The 3 LCPTE-sensitive leukemia cell lines were also sensitive to removal of thiamine from the medium, thus suggesting the mechanism of action of LCPTE involves extracellular thiamine starvation. (aacrjournals.org)
  • The focus on leukemia as a target of thiamine-depleting strategy was prompted by the NCI60 screening panel results, indicating that leukemia cell lines may be more sensitive to thiaminase I treatment than other cell lines. (aacrjournals.org)
  • Upon further testing of other leukemia cell lines, we unexpectedly found that some lymphoblastic leukemia cell lines were extremely sensitive to thiaminase I. (aacrjournals.org)
  • P120 is expressed in all lymphoid and fibroblastic cell lines we have tested that were transformed by A-MuLV but is not detectable in a lymphoid line in which the A-MuLV genome was established by infection but was not responsible for the transformation. (caltech.edu)
  • The idea that T-cell responses can induce remission of acute leukemias is now supported by several lines of evidence. (cqdm.org)
  • The etiology of leukemias cannot entirely be explained by known risk factors, including ionizing radiation, benzene exposure, and infection with human T cell leukemia virus. (ox.ac.uk)
  • From there, the definition branches based on the type of cell that is affected - either myeloid or lymphoid. (cancerhorizons.com)
  • We describe 2 cases of 'bilineal' crisis in chronic myelogenous leukemia (CML) with T cell and myeloid phenotypes. (elsevier.com)
  • We investigated T cell proliferation in murine infection and lymphoid generation systems by comparing the levels of instantaneous BrdU incorporation by the different lymphoid compartments. (jimmunol.org)
  • During the past decade, studies using oligonucleotide arrays and high-throughput sequencing have identified several genetic and transcriptional aberrations in B-cell acute lymphoblastic leukemia (B-ALL) ( 1 ), leading to three conceptual advances. (pnas.org)
  • Hairy cell leukemia (HCL) is an uncommon B-cell lymphoid neoplasia, representing 2---3% of all leukemias. (uanl.mx)
  • 50% of T-cell acute lymphoblastic leukemia (T-ALL) cases carry activating mutations in the Notch1 receptor. (frontiersin.org)
  • 208 ...................................... Leukemia of unspecified cell type. (cdc.gov)
  • Stem cell donor match found for breast cancer survivor who now has leukemia. (wn.com)
  • area that is heavily populated and just a few meters away from the Bulacao Community School with a population of about 4, 000 school children who are particularly vulnerable to cell tower radiation, namely the impairment of memory and learning, cancer, leukemia and the like. (wn.com)
  • Our dear friend, Abigail Marie Tupas, was diagnosed with Acute Lymhpoid Leukemia (ALL) last April 24, 2019. (gogetfunding.com)